


November 3, 2021

Cain Brothers Industry Insights

Healthcare Weekly Market Report



This week's banker commentary:
Updates On The LIBOR Sunset

Industry Insights

Contents

- Industry Insights
- Healthcare M&A Activity
- Healthcare Equity Private Placement Activity
- Public Equity Capital Markets Activity & Indices
- Tax-Exempt Debt Markets
- Corporate High Grade, High Yield & Leveraged Loan Market
- Healthcare News
- Cain Brothers Recent Transactions Spotlight
- Cain Brothers Recent Transactions



Updates On The LIBOR Sunset

Banker Commentary by Joanna Stephenson

The London Interbank Offered Rate, or LIBOR, has historically been the most widely used benchmark interest rate in the world. Due largely to significant concerns about the manipulation of LIBOR, replacing it is an ongoing global effort. A significant amount of progress has been made since the Alternative Reference Rates Committee (ARRC), selected the Secured Overnight Financing Rate (SOFR) as the alternative to USD-LIBOR. Many organizations, both healthcare and other, have continued to use a wait-and-see-approach on existing LIBOR contracts while dealer trading in contracts based on the new reference rate has increased significantly over the past couple years.

Progress

As “end-users,” one of the main obstacles healthcare entities have faced in trying to utilize SOFR is the lack of a term structure. Until recently, SOFR has only been an overnight rate with complicated payment calculation conventions. In July 2021, however, ARRC formally recommended the CME Group’s Term SOFR (Term SOFR) for business loan activity and for derivatives with end-users hedging Term SOFR rates. This positive development means that borrowers will now be able to set a Term SOFR rate in advance and know what interest payment amount will be due the following month. Term SOFR payment calculation conventions can now essentially mirror existing 1-month LIBOR contracts.

SOFR Liquidity Update

While Term SOFR offers benefits compared to the overnight SOFR, it is so newly recommended that several major banks and swap dealers have yet to execute a Term SOFR derivative trade. Overnight SOFR derivative trading activity, however, has picked up significantly over the past year. SOFR derivative trades as a percent of the total LIBOR/SOFR market have increased 12% from the same week last year. Nevertheless, SOFR volume remains significantly behind LIBOR, and the LIBOR market continues to remain more liquid. To contrast the derivative market depth of LIBOR versus SOFR, the following table shows week-ending amounts of continued traded LIBOR versus SOFR.

| Interest Rate Derivatives: Benchmark Data (Source: ISDA®) | | |
|---|-----------------------------------|-------------|
| | Week Ending October 22, 2021 | |
| | Traded Notional (USD billions) | Trade Count |
| USD LIBOR | 1,814 | 12,443 |
| SOFR (overnight) | 412 | 3,597 |
| SOFR (overnight) as % of Total | 19% | 22% |

Industry Insights

Conversion to SOFR Timing

As demonstrated in the chart above, SOFR represents less than a quarter of the total LIBOR and SOFR weekly derivative trades combined. 1-Month LIBOR will cease to be reported in June 2023, but the FRB1, OCC1 and FDIC1 jointly issued supervisory guidance encouraging banks to stop entering into new USD LIBOR contracts by December 31, 2021. Therefore, SOFR volume is expected to pick-up considerably throughout 2022 and, at some point during the year, SOFR volume will likely exceed LIBOR volume and SOFR will become a more liquid market. Additionally, Term SOFR trades are likely to occur and pick up significant volume. Until then, a wait-and-see approach continues to be expected for end-users such as healthcare entities.

Steps to be Taken Ahead of LIBOR Cessation

Most debt and derivative contracts are silent on the occurrence of a cessation of an index reference rate. As we approach June 2023, those that have not remediated their contracts will be scrambling to amend existing documents to convert to a new rate. Waiting until the last minute is not a recommended strategy. Language can be added to documents now that provide for fallback rate determination methodologies when LIBOR does cease to be reported. This language does not need to convert a trade to SOFR or Term SOFR today but can set the groundwork for determining the new reference rate when triggered.

Cain Brothers has extensive experience negotiating this language with banks and dealers and can assist with its incorporation. By the end of 2022 we expect most of our clients will have their LIBOR contracts converted to an alternative rate or have robust fallback language incorporated.

As this topic continues to develop, Cain Brothers will provide updates. Please feel free to contact your banker with questions or our derivative expert, Joanna Stephenson, at 646-205-0276.

Healthcare M&A Activity

Recent Selected Healthcare M&A Transactions (\$MM)

| Date | Target Name | Acquirer | EV | Enterprise Value / | | Description |
|------------|---|---|----------|--------------------|------------|---|
| | | | | LTM Rev. | LTM EBITDA | |
| 10/29/2021 | SpecialtyCare (Kohlberg) | Morgan Stanley Infrastructure Partners | NA | NA | NA | Network of outsourced clinical services to hospital operating rooms |
| 10/26/2021 | TransUnion's Healthcare Business | nTrive (Clearlake Capital) | NA | NA | NA | Healthcare data and analytics business |
| 10/26/2021 | Caring Brands (Levine Leichtman Capital) | Wellspring Capital | NA | NA | NA | Franchisor of home healthcare services: Interim HealthCare, Bluebird Care and Just Better Care |
| 10/25/2021 | CEI Vision Group (Revelstoke Capital Partners) | EyeCare Partners | ~\$600.0 | NA | NA | Ophthalmology management services organization |
| 10/25/2021 | Lemona Health | 23andMe (Nasdaq: ME) | \$400 | NA | NA | On-demand platform for accessing medical care and pharmacy services online |
| 10/25/2021 | MediStreams | TT Capital Partners | NA | NA | NA | Provider of remittance, reconciliation, and payment automation revenue cycle management solutions for healthcare providers |
| 10/26/2021 | WEP Clinical | The Jordan Company | NA | NA | NA | Specialized pharma services company assists pharmaceutical companies to help patients and physicians gain early access to medicines |
| 10/20/2021 | Grace Home Health | Excelin Health (Corinthian Capital) | NA | NA | NA | Provider of in home nursing and therapy care |
| 10/20/2021 | Intouch Group | EVERSANA | NA | NA | NA | Full-service global agency network serving the pharmaceutical industry |
| 10/20/2021 | Outpatient Imaging (ICV Partners) | The Cranemere Group | NA | NA | NA | Outpatient imaging platform developing joint ventures with health systems |
| 10/19/2021 | Agape Care Group* | Ridgemont Equity Partners | NA | NA | NA | Provider of hospice and palliative care in the Southeast |
| 10/19/2021 | Arine | SCAN Group | NA | NA | NA | Tech drive medication management and adherence provider |
| 10/19/2021 | Colorado Retina Associates* | Retina Consultants of America (Webster Equity Partners) | NA | NA | NA | 13 board-certified and fellowship-trained ophthalmologists in the greater Denver-Boulder metropolitan area |
| 10/19/2021 | Genesee Scientific | LLR Partners | NA | NA | NA | Manufacturer and distributor of products to global life science markets |
| 10/19/2021 | Vitality Health Plan and Reliance Healthcare (majority stake) | Commonwealth Care Alliance | NA | NA | NA | Medicare Advantage plans in Massachusetts and California |
| 10/19/2021 | Wellframe | HealthEdge Software (Blackstone) | NA | NA | NA | Digital health management company |
| 10/19/2021 | MDVIP (Leonard Green & Partners and Summit Partners) | Goldman Sachs Asset Management and Charlesbank Capital Partners | NA | NA | NA | Membership-based healthcare with a national network of over 1,100 primary care physicians |
| 10/15/2021 | imre | RLH Equity Partners | NA | NA | NA | Provider of strategic and creative marketing services to enterprise clients in the healthcare sector |
| 10/13/2021 | Carrus (Revelstoke Capital Partners) | Penn Foster | NA | NA | NA | Provider of healthcare continuing education, and certification management |
| 10/13/2021 | Halo Health (Bain Capital) | symplr (Clearlake Capital Group and CharlesBank Capital Partners) | NA | NA | NA | Provider of clinical communications and collaboration SaaS solutions |
| 10/12/2021 | IMMR | Veranex (Summit Partners)* | NA | NA | NA | Provider of preclinical research, pathology evaluation and surgical training services to medical technology industry |

Healthcare Equity Private Placements Activity

Recent Selected Healthcare Equity Private Placements (\$MM)

| Date | Company | Investor(s) | Type | Amount | Description |
|------------|-----------------------------|--|------------------------------|--------------------------------|---|
| 10/26/2021 | Medable | Blackstone Growth and Tiger Global (co-leads), GSR Ventures, Sapphire Ventures and WTI | Series D | \$304.0 \$2.1 bln valuation | Patient-focused clinical research company offering a cloud offering for adoption of digital and decentralized clinical trials |
| 10/26/2021 | Stride | King River Capital (lead), Mastercard, Allstate, Venrock, NEA, and Fidelity's F-Prime Capital | Series C | \$47 | Portable benefits for independent workers for independent workers |
| 10/21/2021 | Workit Health | Insight Partners (lead), CVS Health Ventures, FirstMark Capital, BCBS Venture Fund, and 3L Capital | Series C | \$118 | Provider of virtual substance use disorder treatment |
| 10/20/2021 | Bardavon Health Innovations | Matrix Capital Management (lead), WestCap | Series C | \$90 | Workers' compensation and musculoskeletal health company |
| 10/20/2021 | Saama Technologies | Carlyle, Amgen Ventures, Intermountain Ventures, Merck Global Health Innovation Fund, McKesson Ventures, Northpond Ventures, Pfizer Ventures, and Population Health Partners | Strategic and Majority Stake | \$430 | AI-driven intelligent clinical cloud company serving the life science industry |
| 10/19/2021 | HistoWiz | Vivo Capital (lead), venBio, Asahi Kasei and Jon Oringer | Series A | \$32 | Digital histopathology service company |
| 10/14/2021 | VillageMD | Walgreens Boots Alliance | Undisclosed | \$5,200 | Provider of value-based primary care services |
| 10/13/2021 | Lark Health | Deerfield Management (lead), PFM Health Sciences, Franklin Templeton, King River Capital, Castlepeak, IPD and Olive Tree Capital | Series D | \$100 | AI solutions for virtual chronic and preventative healthcare |
| 10/13/2021 | Lively | B Capital Group (lead), Telstra Ventures and Costanza Ventures | Series C | \$80 | Modern health savings account |
| 10/13/2021 | Sprinter Health | Andreessen Horowitz (lead), General Catalyst, Accel and Google Ventures | Series A | \$33 | On-demand mobile health company that sends full-time nurses and phlebotomists into the home |
| 10/12/2021 | Oshi Health | Flare Capital Partners, Bessemer Venture Partners and Frist Cressey Ventures (co-leads), CVS Health Ventures and Takeda Digital Ventures | Series A | \$23 | Virtual, patient-centered gastrointestinal care |
| 10/11/2021 | Bond Vet | Warburg Pincus | Undisclosed | \$170 | Tech-enabled brand of veterinary care clinics |
| 10/7/2021 | Brave Care | Mednax (lead) | Series B | \$25 | Pediatric healthcare and technology platform |
| 10/6/2021 | Twin Health | ICONIQ Growth, Sequoia Capital India Advisors, Perceptive Advisors, Corner Ventures, LTS Investments, Sofina Société, Helena Group Foundation | Series C | \$140 | Precision health platform for disease management |
| 10/5/2021 | Honor Technology | Baillie Gifford (lead - equity), T. Rowe Price, Prosus Ventures, Andreessen Horowitz, Thrive Capital, FMZ Ventures, Rock Springs Capital, Lighthouse Capital Markets, and TriplePoint Capital Perceptive Advisors (lead - debt), Ares Management | Series E | \$70 (equity) \$300 (debt) | Senior care network and technology platform |
| 9/30/2021 | TrialSpark | Sam Altman and Lachy Groom (co-leads), Sequoia Capital, Thrive Capital, Casdin Capital, Dragoneer, Section 32, John Doerr, Spark Capital, Felicis Ventures, Sound Ventures, and Arrowmark | Series C | \$156 | Technology-driven pharma company that runs end-to-end clinical trials |
| 9/29/2021 | Membersy | Spectrum Equity | Undisclosed | \$66 | Dental clinic membership software firm |


Public Equity Capital Markets Activity & Indices

Equity Indices Information as of October 29, 2021

| Index | Wk Open | Wk Close | Returns | |
|-----------------|---------|----------|---------|--------|
| | | | 52 Week | Weekly |
| DJIA | 35,677 | 35,820 | 34.4% | 0.4% |
| S&P 500 | 4,545 | 4,605 | 39.1% | 1.3% |
| NASDAQ | 15,090 | 15,498 | 38.6% | 2.7% |
| Russell 2000 | 2,291 | 2,297 | 47.1% | 0.3% |
| NYSE Healthcare | 21,962 | 22,151 | 17.7% | 0.9% |

| Cain Brothers Indicies | Returns | |
|-------------------------|---------|--------|
| | 52 Week | Weekly |
| Acute Care | 90.7% | (1.4%) |
| Alternate Site Services | 9.9% | (6.3%) |
| Diagnostics | 32.8% | 1.0% |
| Distribution | 28.2% | (1.4%) |
| Healthcare IT | 9.2% | 1.7% |
| Healthcare REITs | 27.8% | (0.7%) |
| Managed Care | 44.7% | 1.5% |
| Medical Technology | 26.0% | (0.2%) |
| Outsourced Services | 34.5% | (1.4%) |
| Pharma Services | 56.4% | 2.2% |
| Pharmacy | 54.1% | 0.4% |
| Post-Acute Care | (1.6%) | 0.8% |

Cain Brothers Core Healthcare Indices (1YR Performance)



Recent Selected Healthcare IPOs and Follow-Ons (\$MM)

| Issuer (Ticker) | Pricing Date | Offering | Deal Value | Mkt Cap. ¹ | Offer Price | Current / Offer | Description |
|--------------------------------------|--------------|-----------|------------|-----------------------|-------------|-----------------|--|
| Paragon 28 (FNA) | 10/15/2021 | IPO | \$125 | \$1,391 | \$16.00 | 11.3% | Orthopedic medical device company |
| Cue Health (HLTH) | 9/24/2021 | IPO | \$200 | \$2,875 | \$16.00 | (37.9%) | Consumer focused healthcare IT company |
| Definitive Healthcare (DH) | 9/15/2021 | IPO | \$420 | \$4,288 | \$27.00 | 44.7% | Healthcare commercial intelligence solutions |
| Avantor (AVTR) | 9/15/2021 | Follow On | \$875 | \$25,884 | \$42.00 | (8.5%) | Critical products and services to customers in the biopharma and healthcare industries |
| Maravai LifeSciences (Nasdaq: MRVI)* | 9/10/2021 | Follow On | \$1,000 | \$15,400 | \$50.00 | (16.0%) | Data and analytics technology and services to healthcare organizations |

Tax-Exempt Debt Markets

Tax-Exempt Debt Information as of October 29, 2021

| Security | Current (%) | One Week Ago (%) | One Year Ago (%) |
|--|-------------|------------------|------------------|
| A-rated Tax-Exempt Hospital Bonds (30-Yr) | 1.99% | 2.03% | 2.41% |
| AA Tax-Exempt Hospital Bonds (30-Yr) | 1.79% | 1.83% | 2.11% |
| SIFMA (Variable Rate Demand Notes) | 0.05% | 0.05% | 0.12% |
| Revenue Bond Index | 2.61% | 2.64% | 2.76% |
| SIFMA/1 Month LIBOR | 55.56% | 55.56% | 80.00% |
| RBI/30 Yr Treasury (%) | 135.23% | 126.92% | 167.27% |
| 30-Year Floating to Fixed Swap (81% LIBOR) | 1.41% | 1.51% | 1.01% |

Tax-Exempt Healthcare Issuance Information¹ (\$MM)

| Borrower | Par | State | Rating | Maturity | Call, Put or Reprice* | Coupon | Yield to Call | Yield to Mat. | AAA |
|--|--------------------|-------|---------------|----------|-----------------------|--------|---------------|---------------|-------|
| AdventHealth Obligated Group** (Taxable) | \$400.000 | FL | Aa2 / AA / AA | 2051 | MWC** | 2.80% | 2.80% | N/A | 1.95% |
| Purchase Senior Learning Community Inc. Project*** | \$219.130 | NY | NR / NR / NR | 2056 | 2030 (C) | 5.00% | 4.50% | 4.79% | 1.69% |
| Purchase Senior Learning Community Inc. Project | \$89.690 | NY | NR / NR / NR | 2026 | NC | 2.88% | 2.88% | N/A | 1.69% |
| Purchase Senior Learning Community Inc. Project | \$58.775 | NY | NR / NR / NR | 2028 | NC | 3.20% | 3.20% | N/A | 1.69% |
| Purchase Senior Learning Community Inc. Project | \$23.605 | NY | NR / NR / NR | 2029 | NC | 3.60% | 3.60% | N/A | 1.69% |
| Purchase Senior Learning Community Inc. Project (Taxable) | \$6.890 | NY | NR / NR / NR | 2025 | NC | 3.13% | 3.13% | N/A | 0.77% |
| Vanderbilt University Medical Center**** (Taxable) | \$237.565 | TN | A3 / A / NR | 2052 | MWC**** | 3.24% | 3.24% | N/A | 1.96% |
| Vanderbilt University Medical Center | \$57.860 | TN | A3 / A / NR | 2031 | 2031 (C) | 5.00% | 1.68% | 1.82% | 1.69% |
| Penn State Health | \$288.840 | PA | A2 / A+ / NR | 2051 | 2029 (C) | 5.00% | 2.18% | 3.84% | 1.69% |
| Nicklaus Children's Hospital Project | \$161.965 | FL | NR / A / A+ | 2051 | 2031 (C) | 4.00% | 2.56% | 3.34% | 1.69% |
| Nicklaus Children's Hospital Project (Taxable) | \$92.730 | FL | NR / A / A+ | 2042 | MWC | 3.13% | 3.13% | N/A | 2.05% |
| Aspirus, Inc. Obligated Group***** | \$208.295 | WI | A1 / AA- / NR | 2051 | 2031 (C) | 4.00% | 2.54% | 3.33% | 1.69% |
| Montage Health | \$132.780 | CA | NR / AA- / AA | 2046 | 2031 (C) | 4.00% | 2.18% | 3.09% | 1.69% |
| University Hospitals Hlth. Sys. Inc. | \$82.605 | OH | A2 / A / NR | 2041 | 2029 (C) | 4.00% | 2.20% | 3.17% | 1.69% |
| Oak Hammock at the University of Florida Inc. Project***** | \$39.000 | FL | NR / NR / BBB | 2046 | 2031 (C) | 4.00% | 3.41% | 3.71% | 1.69% |
| Oak Hammock at the University of Florida Inc. Project | \$16.645 | FL | NR / NR / BBB | 2046 | 2030 (C) | 4.00% | 2.96% | 3.51% | 1.69% |
| The DCH Health Care Authority | \$31.555 | AL | NR / A / NR | 2051 | 2031 (C) | 4.00% | 2.68% | 3.40% | 1.69% |
| The Jerome Home Issue | \$14.860 | CT | NR / NR / BBB | 2051 | 2031 (C) | 4.00% | 2.97% | 3.53% | 1.69% |
| Kidron Bethel & Schowalter | \$10.560 | KS | NR / NR / NR | 2046 | 2026 (C) | 3.65% | 3.65% | N/A | 1.69% |
| Total | \$2,173.350 | | | | | | | | |

*Key: NC = No Call, MWC = Make Whole Call, (C) = Par Call, (P) = 1st Put, (R) = Reprice Date

**Make Whole Call at 15 bps

***Overlapping final maturity with Coupon / YTC / YTM of 4.50% / 4.63% / NA

****Make Whole Call at Tsy plus 20 bps

*****Overlapping final maturity with Coupon / YTC / YTM of 3.00% / 3.05% / NA

*****Forward Delivery Bonds

1. Bloomberg, Capital IQ

Tax-Exempt Debt Markets

What's On Deck: Tax-Exempt Healthcare Issuances¹ (\$MM)

| Issuer | Date | Amount | Rating |
|---|-----------|-----------|-----------------|
| Beth Israel Lahey Health Taxable Bonds, Series L (2021) | 11/3/2021 | \$500.000 | A3 / A / NR |
| Allina Health System Taxable Bonds Series 2021 | 11/4/2021 | \$303.031 | Aa3 / AA- / AA- |
| City of Minneapolis, Minnesota Health Care System Revenue Bonds Series 2021 (Allina Health System) | 11/4/2021 | \$172.135 | Aa3 / AA- / AA- |
| Economic Development Authority of the City of Lynchburg, Virginia Hospital Revenue and Refunding Bonds (Centra Health Obligated Group) Series 2021 | 11/4/2021 | \$211.955 | Baa1 / A- / A- |
| Idaho Health Facilities Authority Revenue Bonds, Series 2021A (St. Luke's Health System Project) | 11/2/2021 | \$211.885 | A3 / A / NR |
| Palm Beach County Health Facilities Authority Revenue Refunding Bonds (Toby & Leon Cooperman Sinai Residences at Boca Raton) Series 2022 (Forward Delivery) | Week of | \$128.815 | NR / NR / NR |
| Spartanburg Regional Health Services District, Inc. Hospital Revenue Refunding Bonds, Series 2022 (Forward Delivery) | 11/3/2021 | \$101.895 | A3 / A / NR |
| Puerto Rico Industrial, Tourist, Educational, Medical and Environmental Control Facilities Financing Authority Hospital Revenue and Refunding Revenue Bonds, Series 2021 (Hospital Auxilio Mutuo Obligated Group Project) | 11/2/2021 | \$60.005 | NR / BBB+ / NR |
| Public Finance Authority Retirement Facilities First Mortgage Revenue and Revenue Refunding Bonds (The United Methodist Retirement Homes), Series 2021A | 11/4/2021 | \$50.250 | NR / NR / BBB |
| Chester County Health and Education Facilities Authority Revenue Bonds (Simpson Senior Services Project), Series 2021 | 11/4/2021 | \$38.195 | NR / NR / NR |

1. Bloomberg, Capital IQ

Corporate High Grade, High Yield & Leveraged Loan Market

Market Overview


High Yield

- Last week saw a \$1.2 billion inflow, which follows the prior week's inflow of \$2.3 billion. YTD net outflows total \$12.9 billion, which compares to 2020 net inflows of \$44.9 billion


Leveraged Loans

- Leveraged loan funds saw a \$706 million inflow last week. There have been 41 inflows in 2021 totaling \$38.4 billion YTD following net outflows in 2020 totaling \$27.0 billion; Inflows totaled a more modest \$8.0 billion in 3Q21 following \$13.6 billion of inflows in 2Q21

HY Index Yield & Spread (YTD)



Weekly New Issue Volume (\$B)



New-Issue Clearing Yields¹ (\$MM)

| | 1Q21 | 2Q21 | 30-Day Rolling Average | | |
|---------------|-------|-------|------------------------|----------------|----------|
| | | | August 2021 | September 2021 | 10/28/21 |
| Overall | 4.40% | 4.64% | 5.17% | 4.66% | 4.80% |
| 4B | 3.00% | 2.98% | 3.88% | 3.44% | 3.58% |
| 2B | 4.63% | 4.99% | 5.26% | 4.87% | 4.83% |
| Middle Market | 4.79% | 5.15% | 6.02% | 6.21% | 5.82% |

Most Recent Healthcare High-Grade Issuances (\$MM)

| Date | Issuer | Security | Size | Ratings | Coupon | Maturity | Spread | IPT-Pricing |
|-----------|-------------------------------|----------|---------|--------------------|--------|------------|---------|-------------|
| 9/19/2021 | Thermo Fisher Scientific Inc* | Sr Notes | \$1,000 | Baa1 / BBB+ / BBB+ | 0.400% | 4/18/2023 | SOFR+35 | 20 bps |
| 9/19/2021 | Thermo Fisher Scientific Inc* | Sr Notes | \$1,350 | Baa1 / BBB+ / BBB+ | 0.797% | 10/18/2023 | +40 | 15 bps |
| 9/19/2021 | Thermo Fisher Scientific Inc* | Sr Notes | \$500 | Baa1 / BBB+ / BBB+ | 0.440% | 10/18/2023 | SOFR+39 | 15 bps |
| 9/19/2021 | Thermo Fisher Scientific Inc* | Sr Notes | \$2,500 | Baa1 / BBB+ / BBB+ | 1.122% | 10/18/2024 | +50 | 15 bps |
| 9/19/2021 | Thermo Fisher Scientific Inc* | Sr Notes | \$500 | Baa1 / BBB+ / BBB+ | 0.580% | 10/18/2024 | SOFR+53 | 15 bps |

Most Recent Healthcare High-Yield Issuances (\$MM)

| Date | Issuer | Security | Size | Ratings | Coupon | Maturity | Spread | Price Talk |
|------------|-----------------------|----------------|---------|---------|--------|------------|---------|--------------|
| 10/22/2021 | Option Care Health | Sr. Notes | \$500 | B3/B- | 4.375% | 10/31/2029 | 286 bps | 4.50% area |
| 10/19/2021 | Avantor Funding | Sr. Notes | \$800 | B2/BB- | 3.875% | 11/1/2029 | 242 bps | 4.00% area |
| 10/4/2021 | HealthEquity (add-on) | Sr. Notes | \$100 | B3/B | 4.500% | 10/1/2029 | 305 bps | 100.75 |
| 9/30/2021 | Medline | Sr. Sec. Notes | \$4,500 | B1/B- | 3.875% | 4/1/2029 | 251 bps | 3.875%-4.00% |

Most Recent Healthcare Leveraged Loan Issuances (\$MM)

| Date | Issuer | Ownership | Ratings | Use of Proceeds | Size | Pricing | Yield |
|------------|-----------------------------|----------------------|---------|-----------------|-------|----------------------|--------|
| 10/29/2021 | Mission Veterinary Partners | Not Sponsored | B3/B- | Corp Purpose | \$250 | L+400, 0.75% @ 99 | 5.000% |
| 10/28/2021 | Confluent Health | Partners Group | B3/B- | Refinancing | \$465 | L+400, 0.50% @ 99.5 | 4.625% |
| 10/25/2021 | Option Care Health | Not Sponsored | B1/B+ | Refinancing | \$600 | L+275, 0.50% @ 99.5 | 3.375% |
| 10/14/2021 | EyeCare Partners | Partners Group | B3/B | Acquisition | \$440 | L+375, 0.50% @ 99.75 | 4.310% |
| 10/7/2021 | Revint Solutions | New Mountain Capital | B3/B- | Refinancing | \$637 | L+425, 0.50% @ 100 | 4.750% |

Healthcare News

Moody's: Rising Costs Will Slow Hospitals Rebuilding Margins To Pre-COVID-19 Levels¹

Healthcare Finance | October 26, 2021

A shortage of nurses and other workers will continue to erode hospital financial performance into 2022, according to a new Healthcare Quarterly report from Moody's. A rise in COVID-19 cases in various regions of the United States has contributed to a wave of nurses, often burned out, resigning to take care of family, to work in less acute healthcare settings such as ambulatory care or to pursue higher-paying contract opportunities, such as becoming a travel nurse. Hospitals are also having difficulty finding other types of healthcare workers, such as respiratory therapists and imaging technicians, as well as nonclinical workers in areas such as dietary, housekeeping and environmental services.

AdventHealth, Ascension Are Unwinding Chicago-Based Joint Venture Amita Healthcare²

Healthcare Finance | October 25, 2021

AdventHealth and Ascension have announced to unwind their six-year-old Amita Health partnership. Following the transition, AdventHealth and Ascension will operate their individual hospitals and related healthcare facilities in the Chicago area. There were no specific details as to when the break-up is expected to be finalized nor additional details on the reason behind the dissolution of the partnership. The partnership between Adventist Midwest Health and Ascension's Alexian Brothers Health System was expanded in 2018, when 10 Presence Health hospitals joined Ascension. Amita is one of Illinois' largest healthcare systems, with 15 acute care and four specialty hospitals. AdventHealth's four area hospitals and related healthcare facilities will continue to be controlled by AdventHealth. Amita Health president and CEO Keith Parrott will lead the Ascension hospitals in Illinois, while the current executive vice president and chief operating officer at Amita, Thor Thordarson, will lead the AdventHealth hospitals in Illinois. Unwinding would allow both healthcare providers to better meet the "changing needs and expectations" of their respective patients in a "rapidly evolving" healthcare market, the companies said. Nationally, Ascension runs 142 hospitals across 19 states and Washington, while AdventHealth operates facilities within nine states across the United States, including nearly 50 hospitals.

Healthcare Is In An Era Of 'Hyper-Innovation' As Executives Look To Ramp Up Digital Tech: Survey³

Fierce Healthcare | October 29, 2021

Businesses around the world have entered an "era of hyper-innovation," according to Citrix Systems—and the healthcare industry is accelerating into the future at an especially rapid pace. When Citrix surveyed 1,200 business leaders across six different industries, healthcare ranked near the top of the industries adopting new technologies and work models. Among the healthcare leaders surveyed, 92% say their businesses adopted new ways of working and processes during the pandemic, and 82% said they're using new tech tools and infrastructure. Across industries, the businesses that created successful collaborative environments during the pandemic also saw more innovation, including in healthcare. Other those surveyed, 58% of healthcare leaders reported that collaboration within their businesses increased during the pandemic, and 72% reported that innovation increased during the pandemic. Other industries like financial services saw far lower stats, with 36% reporting more collaboration and 48% reporting more innovation during the pandemic. In total, these innovations produced an estimated \$678 billion boost in revenue around the world across the industries surveyed.

Healthcare News Continued...

Medicare Drops End-Stage Renal Disease Payment Rule That Aims To Close Health Equity Gaps¹

Fierce Healthcare | October 31, 2021

The Biden administration dropped a final rule Friday that will reward providers that improve rates of home dialysis and kidney transplants among low-income Medicare and dual-eligible beneficiaries. The Centers for Medicare & Medicaid Services (CMS) finalized a rule that updates payment rates for the End-Stage Renal Disease (ESRD) Prospective Payment System and makes changes to the quality incentive program and ESRD Treatment Choices Model. The goal of the changes is to encourage dialysis providers to decrease disparities in home dialysis and transplant rates, part of a larger effort by the Biden administration. It marks the first CMS Innovation Center model to directly address health equity. According to CMS Office of Minority Health's studies on racial, ethnic and socioeconomic factors, disadvantaged people with Medicare have higher rates of ESRD. They are also more likely to experience higher hospital readmissions and costs, as well as more likely to receive in-center hemodialysis (vs. home dialysis). Studies also indicate non-white ESRD patients are less likely to receive pre-ESRD kidney care, become waitlisted for a transplant, or receive a kidney transplant.

Lyft & Uber's Newest Focus: Trying To Solve A Huge Problem In Healthcare²

Forbes.com | October 27, 2021

Once celebrated for their ingenuity in disrupting the public transportation industry, Uber and Lyft have simultaneously been working on something else: expanding their reach into the multi-trillion dollar healthcare market. Both Lyft and Uber have been diversifying their healthcare related offerings in unique and creative ways. Most notably, both companies pledged their support towards vaccine access during the height of the Covid-19 pandemic. In December of last year when the vaccines were first released, Lyft announced a bold initiative, in conjunction with JPMorgan Chase, Anthem Inc., and United Way: "In a normal year, more than 5.8M Americans delay or miss medical care due to a lack of transportation. As we all know, this is not a normal year. Covid-19 has amplified transportation insecurity, especially for seniors and vulnerable communities. That's why we're mobilizing a coalition of partners with a goal to provide 60 million rides to and from vaccination sites for low-income, uninsured, and at-risk communities, when the vaccine becomes available." As John Zimmer, Co-Founder and President of Lyft explained: "This is an opportunity to use our collective strength to mobilize on a massive scale and serve our communities. We cannot let lack of transportation be a factor in determining whether people have access to healthcare."

Why Spine Surgery Is A Key Outpatient Growth Opportunity³


Brecker's Spine Review | October 19, 2021

The evolution of minimally invasive techniques, cost savings and an aging baby boomer population are some of the factors contributing to the spine market becoming a key outpatient growth opportunity in the coming years. Spine surgery is among the higher-acuity specialties that many ASCs are migrating to their facilities. Integrating spine care into a multispecialty surgery center can significantly boost the growth rate and profit margin of an ASC, which ultimately leads to a considerable increase in the center's equity value. Cost savings continues to be a priority for the U.S. healthcare system as it transitions from a fee-for-service toward a value-based model. CMS and commercial payers are adopting new policies to push these procedures from the inpatient setting to outpatient environments.

November 10, 2021

Cain Brothers Industry Insights

Healthcare Weekly Market Report



**This week's banker commentary:
Where Precision Medicine Efforts Stand**

Industry Insights

Contents

- Industry Insights
- Healthcare M&A Activity
- Healthcare Equity Private Placement Activity
- Public Equity Capital Markets Activity & Indices
- Tax-Exempt Debt Markets
- Corporate High Grade, High Yield & Leveraged Loan Market
- Healthcare News
- Cain Brothers Recent Transactions Spotlight
- Cain Brothers Recent Transactions



Where Precision Medicine Efforts Stand

Banker Commentary by Anita Krishnan

In 2015, President Obama announced the launch of the \$200 million Precision Medicine Initiative, citing personalized medicine as a means to “curing diseases like cancer and diabetes.” Precision medicine is medical care that moves away from the “one drug fits all” model and takes an individual’s genetics, history and lifestyle into account. Since 2015, we have made great strides in this initiative. Today, precision medicines account for more than one out of every four drugs the FDA has approved since 2015. Last year alone, the FDA approved 19 personalized medicines, representing ~39% of all new molecular entities.¹

Up to this point, these strides have been facilitated by advances in genome sequencing and sequencing applications that, in turn, have opened up the broader field of systems biology (i.e., how genes, proteins and other biological components interact). Since completing the Human Genome Project in 2003, scientists have worked to create a more extensive database of individual genomes as they recognized that commercial whole-genome sequencing (“WGS”), as reflected by the human genome project, missed out on pivotal variations amongst individuals. Evan Eichler, a Professor of Genome Sciences at Washington University, suggested that 75% of variants in an individual’s genome are not reflected in commercial WGS. This led to more targeted testing of medically relevant genes / variants, which is less expensive.

The growing database of medically relevant genetic data has led scientists and researchers to focus efforts on identifying more personalized medicines and therapies. For example, DepMap (the Cancer Dependency Map), which, at its simplest, is running an extensive correlation exercise that catalogs cancer mutations and their responsiveness to various drugs. Through this project, ~4,500 drugs have been tested on 578 human cancer cells, leading to the discovery that nearly 50 (non-oncology) drugs had previously unrecognized anti-cancer properties.² Part of the reason for DepMap’s progress is that oncology is the largest adopter of precision medicine. Out of the aforementioned 19 personalized medicines approved last year, nine were for cancer applications.

However, when it comes to non-oncology efforts in precision medicine, the U.S.’s efforts fall behind. In addition to exposing shortcomings in our health system, the COVID-19 pandemic also revealed deficiencies in our sequencing efforts. The U.S. sequenced 200K COVID-19 cases, whereas the U.K. sequenced 75% more (350K)³. As a response to our underperformance, The American Rescue Plan of 2021 directed \$1.75 billion to the CDC to support genomic sequencing and surveillance. Through this initiative, the U.S. will set up an infrastructure that further supports sequencing as a whole and act as a catalyst for future endeavors. Possible outcomes from this effort are the development of genetic data infrastructures, re-assessment / revamp of the current

¹ [Personalized Medicine Coalition](#)

² [Science Daily](#)

³ [McKinsey](#)

Industry Insights

sequencing network (with a specific focus on identifying laboratories with sequencing capacity) and expanding sequencing capabilities.

These improvements will act as a catalyst to the initial goal of the Precision Medicine Initiative and will bridge the gap needed to start looking for applications outside of oncology. Oncology is not the only application that needs precision medicine (although it is understandable why we have prioritized oncology applications). The reality is that drug inefficacy pervades many diseases. For example, 70% of Alzheimer's patients have reported medication inefficacy. The same is true of 75% of cancer patients. Other notable conditions with medication inefficiency include Arthritis (50%), Diabetes (43%), Asthma (40%), and Depression (38%)⁴.

In addition to sequencing developments, precision medicine also benefits from technological advances in diagnostics, digital devices, imaging, analytical tools and therapy selection. These technical solutions have also garnered interest and investment from blue-chip companies. In 2018, Google and Microsoft invested in DNAnexus, a cloud-based platform for genomics and biomedical datasets. Outside of genetics, medical device companies have developed new imaging technologies for digital pathology to detect digital biomarkers: IBM has developed high-performance data and A.I. solutions that aid in developing precision medicine models, while Philips has solutions that quantify the functional activity of cell signaling pathways. The rapidly developing symphony of genetic and non-genetic precision medicine tools and databases portend exciting new developments for both therapeutics as well as refinements in the practice of medicine using existing drugs.

Precision medicine will only continue to grow if it can reach more of the population. Extended reach will only happen if more individual genomes are cataloged along with ongoing access to their developing medical records that allows for researchers to see the full biological picture. The combined efforts of researchers and scientists (focusing on cataloging more individual genomes and medical record databases), corporations (providing technological advances that will allow us to house more data and analyze them expeditiously), and government programs (recognizing the need for and providing funding) should enable us to (1) develop and identify personalized medicines at a faster rate, (2) make meaningful progress in precision oncology medicines, and (3) foray into applying precision medicine to non-oncology applications. Fulfilling these three goals will catalyze our efforts to fulfill the original intent set out in 2015: curing a multitude of diseases.

⁴ Spear, BB, Heath-Chiozzi, Huff, Clinical application of pharmacogenomics, Trends in Molecular Medicine 2001

Healthcare M&A Activity

Recent Selected Healthcare M&A Transactions (\$MM)

| Date | Target Name | Acquirer | EV | Enterprise Value / | | Description |
|------------|---|--|----------|--------------------|------------|---|
| | | | | LTM Rev. | LTM EBITDA | |
| 11/3/2021 | U.S. Medical Management (Centene's majority stake) | Rubicon Founders, Valtruis, Oak HC/FT and HLM Venture Partners | NA | NA | NA | A family of companies that provide home health services as well as an accountable care organization |
| 11/2/2021 | Guidemark Health | Arsenal Capital Partners | NA | NA | NA | Healthcare marketing communications, training, and medical education agency |
| 11/1/2021 | iCare Health Solutions (Pine Tree Equity Partners) | VSP Vision Care* | NA | NA | NA | Integrated specialty network and administrator of comprehensive ocular care services |
| 11/1/2021 | Lighthouse Lab Services (majority stake) | Martis Capital | NA | NA | NA | End-to-end provider of turnkey lab build-out and management services to clinical labs |
| 11/1/2021 | Pinnacle Dermatology Management (Chicago Pacific Founders) | BayPine | NA | NA | NA | Dermatology management services organization |
| 11/1/2021 | Rectangle Health | GI Partners | NA | NA | NA | Provider of healthcare financial technology and patient engagement solutions |
| 10/29/2021 | SpecialtyCare (Kohlberg) | Morgan Stanley Infrastructure Partners | NA | NA | NA | Network of outsourced clinical services to hospital operating rooms |
| 10/26/2021 | TransUnion's Healthcare Business | nTrive (Clearlake Capital) | NA | NA | NA | Healthcare data and analytics business |
| 10/26/2021 | Caring Brands (Levine Leichtman Capital) | Wellspring Capital | NA | NA | NA | Franchisor of home healthcare services: Interim HealthCare, Bluebird Care and Just Better Care |
| 10/25/2021 | CEI Vision Group (Revelstoke Capital Partners) | EyeCare Partners | ~\$600.0 | NA | NA | Ophthalmology management services organization |
| 10/25/2021 | Lemonaid Health | 23andMe (Nasdaq: ME) | \$400 | NA | NA | On-demand platform for accessing medical care and pharmacy services online |
| 10/25/2021 | MediStreams | TT Capital Partners | NA | NA | NA | Provider of remittance, reconciliation, and payment automation revenue cycle management solutions for healthcare providers |
| 10/26/2021 | WEP Clinical* | The Jordan Company | NA | NA | NA | Specialized pharma services company assists pharmaceutical companies to help patients and physicians gain early access to medicines |
| 10/20/2021 | Grace Home Health | Excelin Health (Corinthian Capital) | NA | NA | NA | Provider of in home nursing and therapy care |
| 10/20/2021 | Intouch Group | EVERSANA | NA | NA | NA | Full-service global agency network serving the pharmaceutical industry |
| 10/20/2021 | Outpatient Imaging (ICV Partners) | The Cranemere Group | NA | NA | NA | Outpatient imaging platform developing joint ventures with health systems |
| 10/19/2021 | Agape Care Group* | Ridgemont Equity Partners | NA | NA | NA | Provider of hospice and palliative care in the Southeast |
| 10/19/2021 | Arine | SCAN Group | NA | NA | NA | Tech drive medication management and adherence provider |
| 10/19/2021 | Colorado Retina Associates* | Retina Consultants of America (Webster Equity Partners) | NA | NA | NA | 13 board-certified and fellowship-trained ophthalmologists in the greater Denver-Boulder metropolitan area |
| 10/19/2021 | Genesee Scientific | LLR Partners | NA | NA | NA | Manufacturer and distributor of products to global life science markets |
| 10/19/2021 | Vitality Health Plan and Reliance Healthcare (majority stake) | Commonwealth Care Alliance | NA | NA | NA | Medicare Advantage plans in Massachusetts and California |

Healthcare Equity Private Placements Activity

Recent Selected Healthcare Equity Private Placements (\$MM)

| Date | Company | Investor(s) | Type | Amount | Description |
|------------|-----------------------------|--|----------------------------|--------------------------------|---|
| 11/2/2021 | Infusion for Health | Oak HC/FT (lead), Cimarron Healthcare Capital | Undisclosed | \$50 | Network of ambulatory infusion centers |
| 11/1/2021 | Convergent Dental | Arboretum Ventures (lead), Long River Ventures and the Gund Foundation | Series C | \$40 | Dental equipment company |
| 10/26/2021 | Medable | Blackstone Growth and Tiger Global (co-leads), GSR Ventures, Sapphire Ventures and WTI | Series D | \$304.0 \$2.1 bln valuation | Patient-focused clinical research company offering a cloud offering for adoption of digital and decentralized clinical trials |
| 10/26/2021 | Stride | King River Capital (lead), Mastercard, Allstate, Venrock, NEA, and Fidelity's F-Prime Capital | Series C | \$47 | Portable benefits for independent workers for independent workers |
| 10/21/2021 | Workit Health | Insight Partners (lead), CVS Health Ventures, FirstMark Capital, BCBS Venture Fund, and 3L Capital | Series C | \$118 | Provider of virtual substance use disorder treatment |
| 10/20/2021 | Bardavon Health Innovations | Matrix Capital Management (lead), WestCap | Series C | \$90 | Workers' compensation and musculoskeletal health company |
| 10/20/2021 | Saama Technologies | Carlyle, Amgen Ventures, Intermountain Ventures, Merck Global Health Innovation Fund, McKesson Ventures, Northpond Ventures, Pfizer Ventures, and Population Health Partners | Strategic and Majority Sta | \$430 | AI-driven intelligent clinical cloud company serving the life science industry |
| 10/19/2021 | HistoWiz | Vivo Capital (lead), venBio, Asahi Kasei and Jon Oringer | Series A | \$32 | Digital histopathology service company |
| 10/14/2021 | VillageMD | Walgreens Boots Alliance | Undisclosed | \$5,200 | Provider of value-based primary care services |
| 10/13/2021 | Lark Health | Deerfield Management (lead), PFM Health Sciences, Franklin Templeton, King River Capital, Castlepeak, IPD and Olive Tree Capital | Series D | \$100 | AI solutions for virtual chronic and preventative healthcare |
| 10/13/2021 | Lively | B Capital Group (lead), Telstra Ventures and Costanoa Ventures | Series C | \$80 | Modern health savings account |
| 10/13/2021 | Sprinter Health | Andreessen Horowitz (lead), General Catalyst, Accel and Google Ventures | Series A | \$33 | On-demand mobile health company that sends full-time nurses and phlebotomists into the home |
| 10/12/2021 | Oshi Health | Flare Capital Partners, Bessemer Venture Partners and Frist Cressey Ventures (co-leads), CVS Health Ventures and Takeda Digital Ventures | Series A | \$23 | Virtual, patient-centered gastrointestinal care |
| 10/11/2021 | Bond Vet | Warburg Pincus | Undisclosed | \$170 | Tech-enabled brand of veterinary care clinics |
| 10/7/2021 | Brave Care | Mednax (lead) | Series B | \$25 | Pediatric healthcare and technology platform |
| 10/6/2021 | Twin Health | ICONIQ Growth, Sequoia Capital India Advisors, Perceptive Advisors, Corner Ventures, LTS Investments, Sofina Société, Helena Group Foundation | Series C | \$140 | Precision health platform for disease management |
| 10/5/2021 | Honor Technology | Baillie Gifford (lead - equity), T. Rowe Price, Prosus Ventures, Andreessen Horowitz, Thrive Capital, FMZ Ventures, Rock Springs Capital, Lighthouse Capital Markets, and TriplePoint Capital Perceptive Advisors (lead - debt), Ares Management | Series E | \$70 (equity) \$300 (debt) | Senior care network and technology platform |


Public Equity Capital Markets Activity & Indices

Equity Indices Information as of November 5, 2021

| Index | Wk Open | Wk Close | Returns | |
|-----------------|---------|----------|---------|--------|
| | | | 52 Week | Weekly |
| DJIA | 35,820 | 36,328 | 28.0% | 1.4% |
| S&P 500 | 4,605 | 4,698 | 33.8% | 2.0% |
| NASDAQ | 15,498 | 15,972 | 34.3% | 3.1% |
| Russell 2000 | 2,297 | 2,437 | 46.8% | 6.1% |
| NYSE Healthcare | 22,151 | 23,190 | 20.2% | 4.7% |

| Cain Brothers Indicies | Returns | |
|-------------------------|---------|--------|
| | 52 Week | Weekly |
| Acute Care | 72.7% | 0.3% |
| Alternate Site Services | 5.4% | 7.0% |
| Diagnostics | 22.2% | (2.7%) |
| Distribution | 20.3% | 5.3% |
| Healthcare IT | (3.0%) | (4.5%) |
| Healthcare REITs | 25.3% | 1.5% |
| Managed Care | 22.0% | (0.9%) |
| Medical Technology | 21.1% | 0.6% |
| Outsourced Services | 23.3% | 1.0% |
| Pharma Services | 32.4% | (6.0%) |
| Pharmacy | 47.2% | 5.5% |
| Post-Acute Care | (2.3%) | 5.4% |

Cain Brothers Core Healthcare Indices (1YR Performance)



Recent Selected Healthcare IPOs and Follow-Ons (\$MM)

| Issuer (Ticker) | Pricing Date | Offering | Deal Value | Mkt Cap. ¹ | Offer Price | Current / Offer | Description |
|--------------------------------------|--------------|-----------|------------|-----------------------|-------------|-----------------|--|
| Paragon 28 (FNA) | 10/15/2021 | IPO | \$125 | \$1,391 | \$16.00 | 11.3% | Orthopedic medical device company |
| Cue Health (HLTH) | 9/24/2021 | IPO | \$200 | \$2,875 | \$16.00 | (37.9%) | Consumer focused healthcare IT company |
| Definitive Healthcare (DH) | 9/15/2021 | IPO | \$420 | \$4,288 | \$27.00 | 44.7% | Healthcare commercial intelligence solutions |
| Avantor (AVTR) | 9/15/2021 | Follow On | \$875 | \$25,884 | \$42.00 | (8.5%) | Critical products and services to customers in the biopharma and healthcare industries |
| Maravai LifeSciences (Nasdaq: MRVI)* | 9/10/2021 | Follow On | \$1,000 | \$15,400 | \$50.00 | (16.0%) | Data and analytics technology and services to healthcare organizations |

Tax-Exempt Debt Markets

Tax-Exempt Debt Information as of November 5, 2021

| Security | Current (%) | One Week Ago (%) | One Year Ago (%) |
|--|-------------|------------------|------------------|
| A-rated Tax-Exempt Hospital Bonds (30-Yr) | 1.88% | 1.99% | 2.26% |
| AA Tax-Exempt Hospital Bonds (30-Yr) | 1.68% | 1.79% | 1.96% |
| SIFMA (Variable Rate Demand Notes) | 0.04% | 0.05% | 0.11% |
| Revenue Bond Index | 2.59% | 2.61% | 2.60% |
| SIFMA/1 Month LIBOR | 44.44% | 55.56% | 84.62% |
| RBI/30 Yr Treasury (%) | 138.50% | 135.23% | 162.50% |
| 30-Year Floating to Fixed Swap (81% LIBOR) | 1.36% | 1.41% | 0.97% |

Tax-Exempt Healthcare Issuance Information¹ (\$MM)

| Borrower | Par | State | Rating | Maturity | Call, Put or Reprice* | Coupon | Yield to Call | Yield to Mat. | AAA |
|---|--------------------|-------|-----------------|----------|-----------------------|--------|---------------|---------------|-------|
| Beth Israel Lahey Health** (Taxable) | \$400.000 | MA | A3 / A / NR | 2051 | MWC** | 3.08% | 3.08% | N/A | 1.96% |
| Beth Israel Lahey Health** (Taxable) | \$100.000 | MA | A3 / A / NR | 2028 | MWC** | 2.22% | 2.22% | N/A | 1.42% |
| Allina Health System*** (Taxable) | \$302.323 | MN | Aa3 / AA- / AA- | 2051 | MWC*** | 2.90% | 2.90% | N/A | 1.96% |
| Allina Health System | \$167.770 | MN | Aa3 / AA- / AA- | 2040 | 2031 (C) | 4.00% | 1.86% | 2.69% | 1.58% |
| St. Luke's Health System Project**** | \$218.595 | ID | A3 / A / NR | 2051 | 2032 (C) | 4.00% | 2.41% | 3.24% | 1.58% |
| Centra Health Obligated Group | \$215.430 | VA | Baa1 / A- / A- | 2055 | 2032 (C) | 4.00% | 2.37% | 3.27% | 1.58% |
| Billings Clinic Obligated Group (Taxable) | \$150.000 | MT | NR / AA- / AA- | 2051 | MWC | 3.00% | 3.00% | N/A | 1.96% |
| Billings Clinic Obligated Group (Forward Delivery) | \$49.190 | MT | NR / AA- / AA- | 2037 | 2032 (C) | 4.00% | 2.35% | 2.79% | 1.58% |
| Toby & Leon Cooperman Sinai Residences at Boca Raton (Forward Delivery) | \$125.345 | FL | NR / NR / NR | 2056 | 2030 (C) | 4.25% | 3.88% | 4.11% | 1.58% |
| Spartanburg Regional Health Services District, Inc. (Forward Delivery) | \$102.630 | SC | A3 / A / NR | 2037 | 2032 (C) | 4.00% | 2.12% | 2.62% | 1.58% |
| Hospital Auxilio Mutuo Obligated Group Project | \$57.410 | PR | NR / BBB+ / NR | 2041 | 2031 (C) | 4.00% | 2.49% | 3.12% | 1.58% |
| The United Methodist Retirement Homes | \$49.470 | NC | NR / NR / BBB | 2051 | 2031 (C) | 4.00% | 2.76% | 3.43% | 1.58% |
| Simpson Senior Services Project | \$39.435 | PA | NR / NR / NR | 2051 | 2031 (C) | 4.00% | 3.73% | 3.87% | 1.58% |
| Total | \$1,977.598 | | | | | | | | |

*Key: NC = No Call, MWC = Make Whole Call, (C) = Par Call, (P) = 1st Put, (R) = Reprice Date

**\$400.000MM Tranche: Make Whole Call at 20 bps; \$100.000MM Tranche: Make Whole Call at 15 bps

***Make Whole Call at 15 bps

****Overlapping final maturity with Coupon / YTC / YTM of 3.00% / 3.00% / NA

1. Bloomberg, Capital IQ

What's On Deck: Tax-Exempt Healthcare Issuances¹ (\$MM)

| Issuer | Date | Amount | Rating |
|--|------------|----------|----------------|
| California Statewide Communities Development Authority Insured Revenue Bonds (San Francisco Campus for Jewish Living Project) Series 2021 Insured By: Cal-Mortgage Loan Insurance which provides 'AA-' S&P rating Cain Brothers Sole-Managed Expected Pricing | 11/9/2021 | \$28.410 | NR / AA- / NR |
| Indiana Finance Authority (Greencroft Obligated Group) Revenue and Refunding Revenue Series 2021A & B, Series 2023A (Series 2023A: Forward Delivery Bonds) | 11/10/2021 | \$66.590 | NR / NR / BBB- |
| Colorado Health Facilities Authority Revenue Refunding Bonds, Series 2023A (Frasier Project) (Forward Delivery) | 11/10/2021 | \$36.715 | NR / NR / BB+ |
| Residential Care Facilities for the Elderly Authority of Coweta County Revenue Bonds (Wesley Woods of Newnan -- Peachtree County Project) Series 2021 | Week of | \$15.085 | NR / NR / BB+ |
| Grossmont Healthcare District (San Diego County, California) 2021 General Obligation Refunding Bonds, Series E | 11/9/2021 | \$11.740 | Aa2 / NR / NR |
| Jackson County, Missouri Special Obligation Refunding Bonds (Truman Medical Center D / B / A University Health Project) Series 2021A | 11/9/2021 | \$10.045 | Aa2 / NR / NR |

1. Bloomberg, Capital IQ

Corporate High Grade, High Yield & Leveraged Loan Market

Market Overview

High Yield

- Last week saw a \$1.3 billion outflow, which follows the prior week's inflow of \$1.2 billion. YTD net outflows total \$14.1 billion, which compares to 2020 net inflows of \$44.9 billion


Leveraged Loans

- Leveraged loan funds saw a \$585 million inflow last week. There have been 42 inflows in 2021 totaling \$28.6 billion YTD following net outflows in 2020 totaling \$27.0 billion; Inflows totaled a more modest \$8.0 billion in 3Q21 following \$13.6 billion of inflows in 2Q21

HY Index Yield & Spread (YTD)



Weekly New Issue Volume (\$B)



New-Issue Clearing Yields¹ (\$MM)

| | 2Q21 | 3Q21 | 30-Day Rolling Average | | |
|---------------|-------|-------|------------------------|--------------|----------|
| | | | September 2021 | October 2021 | 11/04/21 |
| Overall | 4.64% | 4.78% | 4.66% | 4.81% | 4.73% |
| 4B | 2.98% | 3.45% | 3.44% | 4.24% | 4.03% |
| 2B | 4.99% | 5.02% | 4.87% | 4.75% | 4.75% |
| Middle Market | 5.15% | 5.75% | 6.21% | 5.82% | 5.40% |

Most Recent Healthcare High-Grade Issuances (\$MM)

| Date | Issuer | Security | Size | Ratings | Coupon | Maturity | Spread | IPT-Pricing |
|-----------|-------------------------------|----------|---------|--------------------|--------|------------|---------|-------------|
| 9/19/2021 | Thermo Fisher Scientific Inc* | Sr Notes | \$1,000 | Baa1 / BBB+ / BBB+ | 0.400% | 4/18/2023 | SOFR+35 | 20 bps |
| 9/19/2021 | Thermo Fisher Scientific Inc* | Sr Notes | \$1,350 | Baa1 / BBB+ / BBB+ | 0.797% | 10/18/2023 | +40 | 15 bps |
| 9/19/2021 | Thermo Fisher Scientific Inc* | Sr Notes | \$500 | Baa1 / BBB+ / BBB+ | 0.440% | 10/18/2023 | SOFR+39 | 15 bps |
| 9/19/2021 | Thermo Fisher Scientific Inc* | Sr Notes | \$2,500 | Baa1 / BBB+ / BBB+ | 1.122% | 10/18/2024 | +50 | 15 bps |
| 9/19/2021 | Thermo Fisher Scientific Inc* | Sr Notes | \$500 | Baa1 / BBB+ / BBB+ | 0.580% | 10/18/2024 | SOFR+53 | 15 bps |

Most Recent Healthcare High-Yield Issuances (\$MM)

| Date | Issuer | Security | Size | Ratings | Coupon | Maturity | Spread | Price Talk |
|-----------|------------------------------------|-----------|---------|---------|--------|-----------|---------|-------------|
| 11/2/2021 | Teva Pharmaceutical Industries (€) | Sr. Notes | \$1,269 | Ba2/BB- | 3.750% | 5/9/2027 | 421 bps | 4.00% area |
| 11/2/2021 | Teva Pharmaceutical Industries (€) | Sr. Notes | \$1,731 | Ba2/BB- | 4.375% | 5/9/2030 | 465 bps | 4.625% area |
| 11/2/2021 | Teva Pharmaceutical Industries | Sr. Notes | \$1,000 | Ba2/BB- | 4.750% | 5/9/2027 | 353 bps | 5.00% area |
| 11/2/2021 | Teva Pharmaceutical Industries | Sr. Notes | \$1,000 | Ba2/BB- | 5.125% | 5/9/2029 | 370 bps | 5.375% area |
| 11/1/2021 | Molina Healthcare | Sr. Notes | \$750 | Ba3/BB- | 3.875% | 5/15/2032 | 228 bps | 4.00% area |

Most Recent Healthcare Leveraged Loan Issuances (\$MM)

| Date | Issuer | Ownership | Ratings | Use of Proceeds | Size | Pricing | Yield |
|------------|-----------------------------|----------------------|---------|-----------------|-------|----------------------|--------|
| 10/29/2021 | Mission Veterinary Partners | Not Sponsored | B3/B- | Corp Purpose | \$250 | L+400, 0.75% @ 99 | 5.000% |
| 10/28/2021 | Confluent Health | Partners Group | B3/B- | Refinancing | \$465 | L+400, 0.50% @ 99.5 | 4.625% |
| 10/25/2021 | Option Care Health | Not Sponsored | B1/B+ | Refinancing | \$600 | L+275, 0.50% @ 99.5 | 3.375% |
| 10/14/2021 | EyeCare Partners | Partners Group | B3/B | Acquisition | \$440 | L+375, 0.50% @ 99.75 | 4.310% |
| 10/7/2021 | Revint Solutions | New Mountain Capital | B3/B- | Refinancing | \$637 | L+425, 0.50% @ 100 | 4.750% |

Healthcare News

How Tech Is Enabling A Personalized Path To Health And Well-Being¹

Fast Company | November 8, 2021

Thanks to AI and advanced data collection, medical researchers are discovering innovative new approaches to preventing disease. For those suffering from Alzheimer's disease, a neurologic disorder characterized by progressive memory loss, the search for a successful treatment has been discouraging. However, one approach has shown promise. Exemplified in the FINGER study, it evaluated lifestyle, nutrition, exercise, and other means of prevention as a way to stave off dementias such as Alzheimer's. For most chronic diseases, the best approach is to intervene early and ideally prevent them from beginning in the first place. Unfortunately, there's no universal approach to prevention. "You have to have enough information about a person," says Dr. Nathan Price, CEO of Onegevity, one of two vertically integrated brands under Thorne HealthTech, a leader in developing innovative solutions for a personalized approach to health and well-being. "There's a whole ecosystem that has to be built around understanding health—and not just studying disease. This is what we call scientific wellness." This includes having models of the body, the right data, and, Price adds, "the right paradigm of understanding health first. It is the bedrock of everything we do."

CMS Finalizes Plans to Hike Price Transparency Penalties, Extend Telehealth Flexibilities²

Healthcare Dive | November 3, 2021

The agency is also moving forward with a plan to stop the ending of the Medicare inpatient-only list, which is a win for hospitals. In dual payment rules out Tuesday, CMS finalized plans increasing hospital fines for not complying with price transparency requirements, halting the end of the Medicare inpatient-only list and furthering some flexibilities for telehealth services. More directly regarding payment rates, the agency included a reduction in the Medicare conversion factor of about 3.85%, although some analysts said it is likely Congress will reverse the change. The American Medical Association called for such action on the Hill, noting the cut "comes at a time when physician practices are still recovering the personal and financial impacts of the COVID public health emergency."

Nearly 60% Of Health Systems Aim To Become 'Payviders' In 2022, Survey Finds³

Fierce Healthcare | November 9, 2021

Nearly 60% of health systems in a new survey plan to get into risk-based Medicare Advantage payment models next year, part of a growing trend of providers seeking to become "payviders" and have a greater role in risk management. The details were part of a survey released Monday conducted by the Healthcare Financial Management Association, which represents hospital executives. The survey of more than 100 health system chief financial officers and other executives was conducted between July and August of this year. It found that health systems are looking to diversify their risk-based payment strategies. For example, 52% of respondents plan to enter into commercial employer-based risk contracts, 49% into Medicare payment models, 36% into managed Medicaid and 33% into direct-to-employer partnerships.

Healthcare News Continued...

COVID-19 Has Brought More Complex, Longer Office Visits¹

Medscape Medical News | November 8, 2021

Increased mental health needs, higher acuity from delayed appointments, and added questions and conversations surrounding COVID-19 are forcing primary care offices to rethink priorities in office visits. Evidence of this came from the latest Primary Care Collaborative (PCC) survey, which found that primary care clinicians are seeing more complex patients requiring longer appointments in the wake of COVID-19. The PCC with the Larry A. Green Center regularly surveys primary care clinicians. This round of questions came August 14-17 and included 1,263 respondents from 49 states, the District of Columbia, and two territories. More than 7 in 10 (71%) respondents said their patients are more complex and nearly the same percentage said appointments are taking more time. Ann Greiner, president and CEO of the PCC, said in an interview that 55% of respondents reported that clinicians are struggling to keep up with pent-up demand after patients have delayed or canceled care. Sixty-five percent in the survey said they had seen a rise in children's mental health issues, and 58% said they were unsure how to help their patients with long COVID.

These Specialties Show The Most Promise For Growth, Says SCA President²

Becker's ASC Review | October 28, 2021

Medical advancements are allowing more procedures to move to the outpatient setting, which creates growth opportunities in the ASC industry. Jason Strauss, president of Deerfield, Ill.-based Surgical Care Affiliates, told "Becker's ASC Review Podcast" that he sees a particularly favorable growth environment in a handful of specialties. One of the areas that we're focused on is cardiology and vascular procedures. We've got several partnerships today, both on the ASC and the [office-based lab] side. And the reality is if you look at claims data from the various Medicare and commercial plans, roughly 98 to 99 percent of that spending is occurring in a hospital-based location. The next that has been continuing to build and grow is total joints and spine procedures. Technology continues to evolve from a pain standpoint to make more and more patients clinically eligible to have those procedures done [in an ASC]. And the reality is there's still a tremendous amount of what I think the ASC industry would consider bread and butter procedures that are still occurring in hospital locations. [There] still is a tremendous opportunity in gastroenterology, neurology and ophthalmology.


1. <https://www.medscape.com/viewarticle/962399>

2. <https://www.beckersasc.com/leadership/these-specialties-show-the-most-promise-for-growth-says-sca-president.html>

November 17, 2021

Cain Brothers Industry Insights

Healthcare Weekly Market Report



This week's banker commentary:
Not-for-Profit Healthcare Organizations Moving Forward

Industry Insights

Contents

- Industry Insights
- Healthcare M&A Activity
- Healthcare Equity Private Placement Activity
- Public Equity Capital Markets Activity & Indices
- Tax-Exempt Debt Markets
- Corporate High Grade, High Yield & Leveraged Loan Market
- Healthcare News
- Cain Brothers Recent Transactions Spotlight
- Cain Brothers Recent Transactions



Not-for-Profit Healthcare Organizations Moving Forward

Banker Commentary by Don Persinski

Long-term taxable and tax-exempt interest rates have remained low, producing a cost of capital advantage for corporations, including 501(c)(3) healthcare organizations. Public and private financial products created opportunities for healthcare organizations to reposition and de-risk their debt portfolios through refinancing strategies.

Despite COVID, severe labor shortages, inflation, market stress from proposed tax increases to individuals and corporations, serious supply chain bottle necks and disruption, and the mandates imposed by the current administration for masks and vaccines, healthcare corporations have also used the low interest rate environment to pursue strategic alliances and major new construction projects.

Healthcare systems, independent hospitals and post-acute care organizations have illustrated their determination to move forward with new construction, expansion projects, building repurposing strategies and start-up post-acute care facilities. Balancing merger, acquisition, joint venture and divestiture strategies with capital budgets for both routine and strategic expenditures have been on the agenda of every healthcare organization.

Headwinds from the construction industry have plagued construction projects and compromised planning due to market volatility for construction materials. The lack of materials, in addition to rising production costs and tariffs, have caused prices for building materials to soar to unprecedented levels. Steel, copper, lumber, and plastic-based material have seen wild price fluctuation. The U.S. Bureau of Labor and Statistics Producer Price Index by Commodity, for example, shows that Metals and Metal Products rose from 196.8 in October 2020 to 648 in September 2021.

Despite this alarming increase, projects are proceeding with health systems intimately reviewing every detail within fixed price contracts, including unit pricing or even cost reimbursable contracts with guaranteed maximum prices. Some contractors are negotiating a material escalation clause. If used, escalation provisions should provide for an equitable adjustment if the price increases exceed a certain threshold of an as-bid price. Some hospitals have agreed to this provision but limited the provision to specific types of materials, while also including a commensurate provision that accounts for any decrease in pricing for materials. In essence, an equitable measure for both parties.

Hospitals need to be cautious and not include a delay provision. Contractors may delay a project or slow down construction with the hope of proceeding when costs of materials decrease. Hospital projects are typically time sensitive and need to move forward. Despite the continued trend toward telehealth, especially for lower acuity needs, health systems continue to make key investments in medical office facilities and inpatient facilities.

Industry Insights

Good Shepherd Rehabilitation Network. In July 2020, Good Shepherd Rehabilitation Network (“Good Shepherd”), a nationally recognized, not-for-profit rehabilitation hospital located in Allentown, Pennsylvania, approved the construction of a new hospital. Good Shepherd includes seven corporations providing health, rehabilitation care, long-term acute care, and service to persons with disabilities, including, but not limited to, the destitute, infants, orphans, paralytics and others with physical handicaps and injuries as well as those persons in the community who, because of their disabilities, are under-served and disadvantaged.

Good Shepherd’s primary inpatient rehabilitation facility, the Allentown Rehab Hospital, was built in 1983, and has 74 licensed and in-use beds. Recognizing the challenges presented by the age and design of the facility, management commissioned a study that concluded that a comprehensive refurbishment would be cost-prohibitive, operationally challenging and, ultimately, might not produce a sufficiently competitive and modern facility.

To remedy the situation, Good Shepherd is constructing a four-story, approximately 120,000 square foot, 76-bed replacement facility in Center Valley, Pennsylvania. As part of the project, Good Shepherd developed overall strategic goals to create a modern, therapeutic environment where patients and families can focus on recovery while introducing patients to new and emerging technologies that can help them recover more quickly and live full and independent lives. In the Good Shepherd system, which will be enhanced with the new hospital, they are conducting important research to advance the understanding of complex medical conditions, such as stroke, multiple sclerosis, brain injury and spinal cord injury.

Although COVID complicated the Good Shepherd planning process, Good Shepherd maintained its conviction and commitment to the community by moving forward with this transformational project.

Total project costs for the replacement hospital are estimated to be approximately \$70.0 million. A major portion of the construction costs will be paid with proceeds from a public bond issue completed by Cain Brothers in September 2021. Despite the challenges to healthcare providers throughout the country and in Good Shepherd’s service area during CY2020 and CY2021, management continued to analyze the project, develop schematics for the replacement hospital, locked in construction costs and ultimately commenced construction.

Three Pillars Senior Living Communities. In March 2021, Wisconsin Masonic Home, Inc., Masonic Center for Health and Rehab, Inc., and Village on the Square, Inc., operating as “Three Pillars Senior Living Communities” issued two series of bonds. A taxable series completed an advance refunding of outstanding debt and proceeds from a tax-exempt series were issued for renovation and expansion projects. Three Pillars renovated its healthcare center to convert 48 semiprivate units with shared bathrooms into 36 private units with private bathrooms. Three Pillars also used this opportunity to expand 20 assisted living beds in 18 units to 75 licensed community-based residential facility beds in 69 units, thus positioning Three Pillars Senior Living Communities to execute their acuity shift strategy. Management developed and executed a transformational renovation and expansion project that expanded assisted living and downsized skilled nursing with a cost of approximately \$28,000,000.

Despite the challenges, it has been refreshing and encouraging to witness the repositioning and continued growth strategies throughout the entire healthcare spectrum.

Healthcare organizations will continue to assess their strategic goals and make difficult decisions, including closing departments and ending services. At least in the short-term, they will also contend with high labor costs and burnout within the entire staff – medical and administrative.

Fortunately, healthcare providers throughout the United States and the aforementioned Cain Brothers clients have chosen to “move forward.” By confronting challenges that are new or unique, and daily challenges that have intensified, they never lost sight of the missions and goals of their health systems and their commitment to support the patients and communities they serve.

Healthcare M&A Activity

Recent Selected Healthcare M&A Transactions (\$MM)

| Date | Target Name | Acquirer | EV | Enterprise Value / | | Description |
|------------|---|--|----------|--------------------|------------|--|
| | | | | LTM Rev. | LTM EBITDA | |
| 11/10/2021 | Integra Managed Care | Anthem (NYSE: ANTM) | NA | NA | NA | Managed Long-Term Care Plan in New York that helps adults with long term care needs and disabilities live safely and independently in their own home |
| 11/10/2021 | Generate Life Sciences (GI Partners)* | CooperCompanies (NYSE: CO) | \$1,600 | 6.4x | NA | Reproductive, newborn stem cell, genetic screening, medical device, and healthcare technology services |
| 11/9/2021 | Leiters (Kaiser Permanente Ventures, Mayo Clinic, Frazier Healthcare Partners, SV Health Investors H.I.G. BioHealth Partners) | Welsh, Carson, Anderson & Stowe | NA | NA | NA | FDA-registered 503B outsourcing provider of high-quality hospital and ophthalmology compounded sterile preparations. |
| 11/8/2021 | BioCare | The Vistria Group | NA | NA | NA | Specialty pharmaceutical distribution partner that provides distribution, specialty pharmacy and logistics services |
| 11/8/2021 | SurgCenter Development | Tenet Healthcare / United Surgical Partners International | \$1,200 | NA | NA | 92 ASCs and related ambulatory support services |
| 11/8/2021 | U.S. Oral Surgery Management (RiverGlade Capital) | Oak Hill Capital | NA | NA | NA | Provider of oral surgery management, partnering with over 140 oral surgeons across 18 states |
| 11/3/2021 | U.S. Medical Management (Centene's majority stake) | Rubicon Founders, Valtruis, Oak HC/FT and HLM Venture Partners | NA | NA | NA | A family of companies that provide home health services as well as an accountable care organization |
| 11/2/2021 | Guidemark Health | Arsenal Capital Partners | NA | NA | NA | Healthcare marketing communications, training, and medical education agency |
| 11/1/2021 | iCare Health Solutions (Pine Tree Equity Partners) | VSP Vision Care* | NA | NA | NA | Integrated specialty network and administrator of comprehensive ocular care services |
| 11/1/2021 | Lighthouse Lab Services (majority stake) | Martis Capital | NA | NA | NA | End-to-end provider of turnkey lab build-out and management services to clinical labs |
| 11/1/2021 | Pinnacle Dermatology Management (Chicago Pacific Founders) | BayPine | NA | NA | NA | Dermatology management services organization |
| 11/1/2021 | Rectangle Health | GI Partners | NA | NA | NA | Provider of healthcare financial technology and patient engagement solutions |
| 10/29/2021 | SpecialtyCare (Kohlberg) | Morgan Stanley Infrastructure Partners | NA | NA | NA | Network of outsourced clinical services to hospital operating rooms |
| 10/26/2021 | TransUnion's Healthcare Business | nTrive (Clearlake Capital) | NA | NA | NA | Healthcare data and analytics business |
| 10/26/2021 | Caring Brands (Levine Leichtman Capital) | Wellspring Capital | NA | NA | NA | Franchisor of home healthcare services: Interim HealthCare, Bluebird Care and Just Better Care |
| 10/25/2021 | CEI Vision Group (Revelstoke Capital Partners) | EyeCare Partners | ~\$600.0 | NA | NA | Ophthalmology management services organization |
| 10/25/2021 | Lemonaid Health | 23andMe (Nasdaq: ME) | \$400 | NA | NA | On-demand platform for accessing medical care and pharmacy services online |
| 10/25/2021 | MediStreams | TT Capital Partners | NA | NA | NA | Provider of remittance, reconciliation, and payment automation revenue cycle management solutions for healthcare providers |
| 10/26/2021 | WEP Clinical* | The Jordan Company | NA | NA | NA | Specialized pharma services company assists pharmaceutical companies to help patients and physicians gain early access to medicines |
| 10/20/2021 | Grace Home Health | Excelin Health (Corinthian Capital) | NA | NA | NA | Provider of in home nursing and therapy care |

Healthcare Equity Private Placements Activity

Recent Selected Healthcare Equity Private Placements (\$MM)

| Date | Company | Investor(s) | Type | Amount | Description |
|------------|-----------------------------|--|------------------------------|--------------------------------|---|
| 11/8/2021 | Enhance Health | Bain Capital Insurance | Undisclosed | \$150 | Digital health insurance brokerage and care navigation platform focused on serving the Medicare Advantage market |
| 11/2/2021 | Infusion for Health | Oak HC/FT (lead), Cimarron Healthcare Capital | Undisclosed | \$50 | Network of ambulatory infusion centers |
| 11/1/2021 | Convergent Dental | Arboretum Ventures (lead), Long River Ventures and the Gund Foundation | Series C | \$40 | Dental equipment company |
| 10/26/2021 | Medable | Blackstone Growth and Tiger Global (co-leads), GSR Ventures, Sapphire Ventures and WTI | Series D | \$304.0 \$2.1 bln valuation | Patient-focused clinical research company offering a cloud offering for adoption of digital and decentralized clinical trials |
| 10/26/2021 | Stride | King River Capital (lead), Mastercard, Allstate, Venrock, NEA, and Fidelity's F-Prime Capital | Series C | \$47 | Portable benefits for independent workers for independent workers |
| 10/21/2021 | Workit Health | Insight Partners (lead), CVS Health Ventures, FirstMark Capital, BCBS Venture Fund, and 3L Capital | Series C | \$118 | Provider of virtual substance use disorder treatment |
| 10/20/2021 | Bardavon Health Innovations | Matrix Capital Management (lead), WestCap | Series C | \$90 | Workers' compensation and musculoskeletal health company |
| 10/20/2021 | Saama Technologies | Carlyle, Amgen Ventures, Intermountain Ventures, Merck Global Health Innovation Fund, McKesson Ventures, Northpond Ventures, Pfizer Ventures, and Population Health Partners | Strategic and Majority Stake | \$430 | AI-driven intelligent clinical cloud company serving the life science industry |
| 10/19/2021 | HistoWiz | Vivo Capital (lead), venBio, Asahi Kasei and Jon Oringer | Series A | \$32 | Digital histopathology service company |
| 10/14/2021 | VillageMD | Walgreens Boots Alliance | Undisclosed | \$5,200 | Provider of value-based primary care services |
| 10/13/2021 | Lark Health | Deerfield Management (lead), PFM Health Sciences, Franklin Templeton, King River Capital, Castlepeak, IPD and Olive Tree Capital | Series D | \$100 | AI solutions for virtual chronic and preventative healthcare |
| 10/13/2021 | Lively | B Capital Group (lead), Telstra Ventures and Costanoa Ventures | Series C | \$80 | Modern health savings account |
| 10/13/2021 | Sprinter Health | Andreessen Horowitz (lead), General Catalyst, Accel and Google Ventures | Series A | \$33 | On-demand mobile health company that sends full-time nurses and phlebotomists into the home |
| 10/12/2021 | Oshi Health | Flare Capital Partners, Bessemer Venture Partners and Frist Cressey Ventures (co-leads), CVS Health Ventures and Takeda Digital Ventures | Series A | \$23 | Virtual, patient-centered gastrointestinal care |
| 10/11/2021 | Bond Vet | Warburg Pincus | Undisclosed | \$170 | Tech-enabled brand of veterinary care clinics |
| 10/7/2021 | Brave Care | Mednax (lead) | Series B | \$25 | Pediatric healthcare and technology platform |
| 10/6/2021 | Twin Health | ICONIQ Growth, Sequoia Capital India Advisors, Perceptive Advisors, Corner Ventures, LTS Investments, Sofina Société, Helena Group Foundation | Series C | \$140 | Precision health platform for disease management |


Public Equity Capital Markets Activity & Indices

Equity Indices Information as of November 12, 2021

| Index | Wk Open | Wk Close | Returns | |
|-----------------|---------|----------|---------|--------|
| | | | 52 Week | Weekly |
| DJIA | 36,328 | 36,100 | 24.1% | (0.6%) |
| S&P 500 | 4,698 | 4,683 | 32.4% | (0.3%) |
| NASDAQ | 15,972 | 15,861 | 35.5% | (0.7%) |
| Russell 2000 | 2,437 | 2,412 | 41.2% | (1.0%) |
| NYSE Healthcare | 22,151 | 23,190 | 20.2% | 4.7% |

| Cain Brothers Indicies | Returns | |
|-------------------------|---------|--------|
| | 52 Week | Weekly |
| Acute Care | 63.3% | (0.4%) |
| Alternate Site Services | (1.5%) | (2.3%) |
| Diagnostics | 30.1% | 2.8% |
| Distribution | 17.3% | 0.4% |
| Healthcare IT | 7.9% | (1.9%) |
| Healthcare REITs | 15.6% | 0.2% |
| Managed Care | 22.6% | 0.7% |
| Medical Technology | 18.4% | (0.1%) |
| Outsourced Services | 27.5% | 2.7% |
| Pharma Services | 40.1% | 3.2% |
| Pharmacy | 31.5% | (0.2%) |
| Post-Acute Care | 18.3% | (1.2%) |

Cain Brothers Core Healthcare Indices (1YR Performance)



Recent Selected Healthcare IPOs and Follow-Ons (\$MM)

| Issuer (Ticker) | Pricing Date | Offering | Deal Value | Mkt Cap. ¹ | Offer Price | Current / Offer | Description |
|--------------------------------------|--------------|-----------|------------|-----------------------|-------------|-----------------|--|
| Paragon 28 (FNA) | 10/15/2021 | IPO | \$125 | \$1,391 | \$16.00 | 11.3% | Orthopedic medical device company |
| Cue Health (HLTH) | 9/24/2021 | IPO | \$200 | \$2,875 | \$16.00 | (37.9%) | Consumer focused healthcare IT company |
| Definitive Healthcare (DH) | 9/15/2021 | IPO | \$420 | \$4,288 | \$27.00 | 44.7% | Healthcare commercial intelligence solutions |
| Avantor (AVTR) | 9/15/2021 | Follow On | \$875 | \$25,884 | \$42.00 | (8.5%) | Critical products and services to customers in the biopharma and healthcare industries |
| Maravai LifeSciences (Nasdaq: MRVI)* | 9/10/2021 | Follow On | \$1,000 | \$15,400 | \$50.00 | (16.0%) | Data and analytics technology and services to healthcare organizations |

Tax-Exempt Debt Markets

Tax-Exempt Debt Information as of November 12, 2021

| Security | Current (%) | One Week Ago (%) | One Year Ago (%) |
|--|-------------|------------------|------------------|
| A-rated Tax-Exempt Hospital Bonds (30-Yr) | 1.83% | 1.88% | 2.25% |
| AA Tax-Exempt Hospital Bonds (30-Yr) | 1.63% | 1.68% | 1.95% |
| SIFMA (Variable Rate Demand Notes) | 0.04% | 0.04% | 0.11% |
| Revenue Bond Index | 2.46% | 2.46% | 2.70% |
| SIFMA/1 Month LIBOR | 44.44% | 44.44% | 78.57% |
| RBI/30 Yr Treasury (%) | 126.15% | 131.55% | 163.64% |
| 30-Year Floating to Fixed Swap (81% LIBOR) | 1.44% | 1.36% | 1.01% |

Tax-Exempt Healthcare Issuance Information¹ (\$MM)

| Borrower | Par | State | Rating | Maturity | Call, Put or Reprice* | Coupon | Yield to Call | Yield to Mat. | AAA |
|---|------------------|-------|----------------|----------|-----------------------|--------|---------------|---------------|-------|
| San Francisco Campus for Jewish Living Project** | \$28.030 | CA | NR / AA- / NR | 2051 | 2031 (C) | 4.00% | 2.08% | 3.11% | 1.53% |
| Greencroft Obligated Group*** | \$34.395 | IN | NR / NR / BBB- | 2037 | 2033 (C) | 4.00% | 3.63% | 3.71% | 1.53% |
| Greencroft Obligated Group | \$32.935 | IN | NR / NR / BBB- | 2051 | 2031 (C) | 4.00% | 2.74% | 3.42% | 1.53% |
| Greencroft Obligated Group | \$0.385 | IN | NR / NR / BBB- | 2023 | NC | 3.25% | 3.25% | N/A | 0.51% |
| Frasier Project*** | \$35.455 | CO | NR / NR / BB+ | 2048 | 2031 (C) | 4.00% | 3.51% | 3.78% | 1.53% |
| Wesley Woods of Newnan – Peachtree City Project | \$15.145 | GA | NR / NR / BB+ | 2046 | 2031 (C) | 4.00% | 3.05% | 3.53% | 1.53% |
| Loomis Obligated Group*** | \$13.755 | MA | NR / BBB / NR | 2051 | 2030 (C) | 4.00% | 3.20% | 3.71% | 1.53% |
| Loomis Obligated Group | \$6.005 | MA | NR / BBB / NR | 2051 | 2030 (C) | 4.00% | 2.65% | 3.46% | 1.53% |
| Grossmont Healthcare District | \$11.670 | CA | Aa2 / NR / NR | 2034 | 2025 (C) | 5.00% | 1.07% | 3.61% | 1.53% |
| Truman Medical Center D/B/A University Health Project | \$9.760 | MO | Aa2 / NR / NR | 2027 | NC | 5.00% | 1.11% | N/A | 1.53% |
| Total | \$187.535 | | | | | | | | |

*Key: NC = No Call, MWC = Make Whole Call, (C) = Par Call, (P) = 1st Put, (R) = Reprice Date

**Cain Brothers Sole-Managed Transaction; Insured By: Cal-Mortgage Insurance which provides 'AA-' S&P rating

***Forward Delivery Bonds

1. Bloomberg, Capital IQ

1. Bloomberg, Capital IQ

What's On Deck: Tax-Exempt Healthcare Issuances¹ (\$MM)

| Issuer | Date | Amount | Rating |
|--|------------|-------------|-----------------|
| South Dakota Health and Educational Facilities Authority Taxable Revenue Bonds, Series 2021 (Sanford) Cain Brothers Sole-Managed Expected Pricing | 11/18/2021 | \$250.000 | NR / A+ / AA- |
| California Health Facilities Financing Authority Revenue Bonds (Cedars-Sinai Health System) Series 2021A | 11/17/2021 | \$1,050.000 | Aa3 / AA- / AA- |
| Cedars-Sinai Health System Taxable Bonds Series 2021 (Corporate CUSIP) | 11/17/2021 | \$300.000 | Aa3 / AA- / AA- |
| Colorado Health Facilities Authority Revenue Bonds (Aberdeen Ridge), Series 2021 | 11/18/2021 | \$143.080 | NR / NR / NR |
| Public Finance Authority Revenue Bonds Bayhealth Medical Center Project Series 2021A (Tax-Exempt) Series 2021B (Taxable) | 11/16/2021 | \$113.970 | NR / AA- / AA |
| Broome County Local Development Corporation Revenue Refunding Bonds (Good Shepherd Village at Endwell, Inc. Project) Series 2021 | 11/18/2021 | \$51.915 | NR / NR / BBB- |
| State of Ohio Healthcare Facility Revenue Bonds Series 2021B & Series 2023 (Otterbein Homes Obligated Group) | 11/17/2021 | \$45.705 | NR / A / NR |
| North Carolina Medical Care Commission Retirement Facilities First Mortgage Revenue and Refunding Revenue Bonds (Plantation Village) Series 2021A | 11/17/2021 | \$32.520 | NR / NR / BBB |
| Maine Health and Higher Educational Facilities Authority Revenue Bonds, Series 2021C Insured By: Assured Guaranty Municipal Corp. which provides 'A1' Moody's rating and 'AA' S&P rating | 11/17/2021 | \$20.070 | A1 / AA / NR |

1. Bloomberg, Capital IQ

Corporate High Grade, High Yield & Leveraged Loan Market

Market Overview


High Yield

- Last week saw a \$2.6 billion inflow, which follows the prior week's outflow of \$1.3 billion. YTD net outflows total \$11.6 billion, which compares to 2020 net inflows of \$44.9 billion


Leveraged Loans

- Leveraged loan funds saw a \$968 million inflow last week. There have been 43 inflows in 2021 totaling \$29.6 billion YTD following net outflows in 2020 totaling \$27.0 billion; Inflows totaled a more modest \$8.0 billion in 3Q21 following \$13.6 billion of inflows in 2Q21

HY Index Yield & Spread (YTD)



Weekly New Issue Volume (\$B)



New-Issue Clearing Yields¹ (\$MM)

| | 2Q21 | 3Q21 | 30-Day Rolling Average | | |
|---------------|-------|-------|------------------------|--------------|----------|
| | | | September 2021 | October 2021 | 11/10/21 |
| Overall | 4.64% | 4.78% | 4.66% | 4.82% | 4.66% |
| 4B | 2.98% | 3.45% | 3.44% | 0.02% | 3.43% |
| 2B | 4.99% | 5.02% | 4.87% | 4.76% | 4.73% |
| Middle Market | 5.15% | 5.75% | 6.21% | 5.82% | 5.40% |

Most Recent Healthcare High-Grade Issuances (\$MM)

| Date | Issuer | Security | Size | Ratings | Coupon | Maturity | Spread | IPT-Pricing |
|-----------|-------------------------------|----------|---------|--------------------|--------|------------|---------|-------------|
| 9/19/2021 | Thermo Fisher Scientific Inc* | Sr Notes | \$1,000 | Baa1 / BBB+ / BBB+ | 0.400% | 4/18/2023 | SOFR+35 | 20 bps |
| 9/19/2021 | Thermo Fisher Scientific Inc* | Sr Notes | \$1,350 | Baa1 / BBB+ / BBB+ | 0.797% | 10/18/2023 | +40 | 15 bps |
| 9/19/2021 | Thermo Fisher Scientific Inc* | Sr Notes | \$500 | Baa1 / BBB+ / BBB+ | 0.440% | 10/18/2023 | SOFR+39 | 15 bps |
| 9/19/2021 | Thermo Fisher Scientific Inc* | Sr Notes | \$2,500 | Baa1 / BBB+ / BBB+ | 1.122% | 10/18/2024 | +50 | 15 bps |
| 9/19/2021 | Thermo Fisher Scientific Inc* | Sr Notes | \$500 | Baa1 / BBB+ / BBB+ | 0.580% | 10/18/2024 | SOFR+53 | 15 bps |

Most Recent Healthcare High-Yield Issuances (\$MM)

| Date | Issuer | Security | Size | Ratings | Coupon | Maturity | Spread | Price Talk |
|-----------|------------------------------------|-----------|---------|---------|--------|-----------|---------|-------------|
| 11/2/2021 | Teva Pharmaceutical Industries (€) | Sr. Notes | \$1,269 | Ba2/BB- | 3.750% | 5/9/2027 | 421 bps | 4.00% area |
| 11/2/2021 | Teva Pharmaceutical Industries (€) | Sr. Notes | \$1,731 | Ba2/BB- | 4.375% | 5/9/2030 | 465 bps | 4.625% area |
| 11/2/2021 | Teva Pharmaceutical Industries | Sr. Notes | \$1,000 | Ba2/BB- | 4.750% | 5/9/2027 | 353 bps | 5.00% area |
| 11/2/2021 | Teva Pharmaceutical Industries | Sr. Notes | \$1,000 | Ba2/BB- | 5.125% | 5/9/2029 | 370 bps | 5.375% area |
| 11/1/2021 | Molina Healthcare | Sr. Notes | \$750 | Ba3/BB- | 3.875% | 5/15/2032 | 228 bps | 4.00% area |

Most Recent Healthcare Leveraged Loan Issuances (\$MM)

| Date | Issuer | Ownership | Ratings | Use of Proceeds | Size | Pricing | Yield |
|------------|----------------------------------|------------------------|---------|-----------------|-------|----------------------|--------|
| 11/8/2021 | Summit Behavioral Healthcare LLC | Patient Square Capital | B3/B- | LBO | \$459 | L+475, 0.75% @ 97 | 6.250% |
| 10/29/2021 | Mission Veterinary Partners | Not Sponsored | B3/B- | Corp Purpose | \$250 | L+400, 0.75% @ 99 | 5.000% |
| 10/28/2021 | Confluent Health | Partners Group | B3/B- | Refinancing | \$465 | L+400, 0.50% @ 99.5 | 4.625% |
| 10/25/2021 | Option Care Health | Not Sponsored | B1/B+ | Refinancing | \$600 | L+275, 0.50% @ 99.5 | 3.375% |
| 10/14/2021 | EyeCare Partners | Partners Group | B3/B | Acquisition | \$440 | L+375, 0.50% @ 99.75 | 4.310% |

Healthcare News

Part B Premiums Set to Rise in 2022 as Medicare Braces for Potential High-Cost Therapies Like Aduhelm¹

Fierce Healthcare | November 12, 2021

Medicare Part B prices are set to rise in 2022, in part because the Biden administration is looking to establish a reserve for unexpected increases in healthcare spending. Part B premiums are set to increase from \$148.50 to \$170.10 in 2022. Annual deductibles will also increase in tandem from \$203 to \$233. Part B covers physician services, outpatient hospital care, certain home health services, durable medical equipment and other health needs that are not covered under the Part A medical benefit. Medicare Part B premiums are legally required to equal 25% of estimated total costs in Part B for people aged 65 and over. CMS is also tasked with setting premiums that ensure the program will be adequately funded. CMS said that while premiums will rise, beneficiaries should see an increase in their Social Security benefits. For example, someone earning \$1,565 per month at present will see a net increase of \$70.40 each month, the agency said. Open enrollment for Medicare ends Dec. 7.

GE, J&J to Split Off Healthcare, Medical Device/Pharma Businesses²

Medtech Intelligence | November 12, 2021

Early this week General Electric Company announced that it would spin off its healthcare division, and today Johnson & Johnson released its plan to separate its businesses—one focused on drugs and medical devices and the other on consumer health products—into two separate companies. GE plans to spin off its healthcare business, which generated \$17 billion in revenue last year, in early 2023 (the company is also spinning off its energy business and will be left with its aviation business). The company states the move will make its businesses stronger and in a position to achieve long-term growth. “The world demands—and deserves—we bring our best to solve the biggest challenges in flight, healthcare, and energy,” stated GE Chairman and CEO H. Lawrence Culp, Jr. in a company press release. “By creating three industry-leading, global public companies, each can benefit from greater focus, tailored capital allocation, and strategic flexibility to drive long-term growth and value for customers, investors, and employees. We are putting our technology expertise, leadership, and global reach to work to better serve our customers.” The healthcare division, which has yet to be named, will be led by Peter Arduini, who will take on the role of president and CEO of GE Healthcare on January 1, 2022.

Behavioral Health Providers Falling Behind in EHR Adoption, Critical to Participate in Value-Based Care³

Behavioral Health Business | November 13, 2021

As a majority of the medical and healthcare community have made the transition to electronic health records over the past decade, behavioral health providers have fallen behind in adopting EHRs in their process, which can cause difficulties for integrating care for behavioral health patients. At a September public meeting for the Medicaid and CHIP Payment and Access Commission (MACPAC), a panel of experts detailed the reasons for the lack of EHRs in behavioral health, what options are out there now and what changes can be made in the near future to get behavioral health providers up to speed when dealing with records. Psychiatric hospitals are using EHRs at 46% rate, compared to 96% in general medicine and surgical practices. That same number for office-based physicians practice psychiatry is 61% compared to over 93% in everything from general practice and surgery to urology and cardiology.

Healthcare News Continued...

FDA Hopes Draft Guidance on Device Software Will Offer 'Clarity, Simplicity'¹

Healthcare IT News | November 8, 2021

The FDA's draft recommendations pertain to device software functions – software in a medical device (SiMD) and software as a medical device (SaMD), most notably – and describe data that would be generated and documented during software design, development, verification and validation. The guidance, once finalized after a public comment period, would replace the FDA's more than 16-year-old Guidance for the Content of Premarket Submissions for Software Contained in Medical Devices. It represents a substantial reworking of that document, which was first issued in May 2005, when the existing technology landscape could hardly have been imagined. Just as the maturity and capabilities of medical devices have evolved significantly since then, so has the agency's regulatory approach.

Report: Nursing Homes Shed 221K Jobs Since Start Of Pandemic While Other Sectors Have Recovered²

Fierce Healthcare | November 11, 2021

Nursing homes have lost 221,000 jobs since the start of the COVID-19 pandemic, the most among all healthcare providers, a new industry report finds. The report, released Wednesday by the American Health Care Association and the National Center for Assisted Living, shows that while other healthcare employment sectors have recovered some of their job losses, recovery for nursing homes remains stagnant. The group analyzed employment numbers from the Bureau of Labor Statistics since March 2020 when the pandemic reached full swing in the U.S. It showed employment in nursing homes declined by 220,000 from 1.58 million in March 2020 to 1.36 million in October 2021. Assisted living centers also lost 38,000 jobs in that time period.

Diabetes Is A 'Pandemic Of Unprecedented Magnitude,' And Experts Fear Covid-19 May Make It Worse³


CNN | November 14, 2021

The year 2021 marks 100 years since the discovery of insulin, a game-changing drug in the fight against diabetes. Despite a century of advancements in treatment, education and prevention, World Diabetes Day 2021 occurs in the wake of grim statistics. One in 10 adults around the world -- some 537 million people -- are currently living with diabetes, according to figures recently released by the International Diabetes Federation (IDF). By 2045, the IDF predicted that the number of people with diabetes is expected to rise to 1 in 8 adults. Nearly 7 million adults have died worldwide in 2021 so far due to diabetes or its complications, the IDF estimated -- that's more than 1 in 10 global deaths from any cause. The pandemic also took a toll on how well people have managed their diabetes over the past year and a half, said Boulton, who is also a professor of medicine at the University of Manchester in the UK.

November 24, 2021

Cain Brothers Industry Insights

Healthcare Weekly Market Report




This week's banker commentary:
Health Systems Expanding Principal Investing Capabilities

Industry Insights

Contents

- Industry Insights
- Healthcare M&A Activity
- Healthcare Equity Private Placement Activity
- Public Equity Capital Markets Activity & Indices
- Tax-Exempt Debt Markets
- Corporate High Grade, High Yield & Leveraged Loan Market
- Healthcare News
- Cain Brothers Recent Transactions Spotlight
- Cain Brothers Recent Transactions



Health Systems Expanding Principal Investing Capabilities

Banker Commentary by Nick Davis

Record amounts of capital have flooded the private capital markets, arming private equity and venture capital firms with a war chest of investable cash exceeding \$2 trillion. With an ever-increasing focus on the broader healthcare sector, companies from the early-stage startup to near-maturation have a myriad of options when it comes to evaluating and ultimately selecting a capital partner. Historically, hospitals and health systems, particularly in the not-for-profit category, have allocated a portion of their earmarked investment dollars toward these asset classes with the goal of generating a return to further support their long-term capital needs. In recent years, however, these same organizations have been building teams and capabilities to participate in these types of private investments as principal investors, offering unique attributes not otherwise available to target companies.

Aligning with their own broader missions and visions, a number of the country's leading health systems have formed in-house venture arms to pursue direct investments. Health systems target opportunities as both primary and secondary investors, the latter utilizing a consortium model where there is participation from venture capital / private equity firms and potentially additional health systems. While not limited to specific sectors, target investments typically are borne out of areas where health systems see ample opportunity to implement a certain product or solution into their own continuum of care. In the last year, related transactions include Advocate Aurora Enterprises acquiring Senior Helpers¹ for approximately \$180 million to further enhance the system's suite of senior services, while separately Ascension Ventures led a \$77 million financing round in Cala Health, a developer of wearable neuromodulation therapy products. Along these lines, a key differentiator that health systems can offer to prospective companies is access to their robust ecosystems and internal support. Attributes include fully staffed research capabilities, leading industry expertise, and an ability to efficiently roll out products and services to an immediate customer base.

Given that the shift to principal investing from the health system perspective has picked up primarily in the last few years, successful exits are beginning to take shape, providing

¹ Cain Brothers served as the lead financial advisor to Senior Helpers in its sale to Advocate Aurora Enterprises, Inc., a wholly owned subsidiary of Advocate Aurora Health, Inc.

Industry Insights

a roadmap and proof of concept. Recent examples include Lumere2, a technology-enabled decision support tool of which Spectrum Health Ventures was an investor, and Ivantis, a glaucoma-focused medical device organization that included Ascension Ventures and MemorialCare Innovation Fund as investors. In the case of Lumere, in addition to Spectrum Health participating as an investor, the health system was also a customer, further highlighting the uniqueness of which companies can leverage the size and scale of a leading health system to refine and expand their own services.

Currently, the majority of health system venture funds are targeting investment in the sub-\$5 – 10 million check size. While this level of investment lends itself to focusing on early-stage investment opportunities, as health systems continue to build out their investment teams, processes, and capital allocation, there will be a natural shift toward larger, more established investments that are typical of traditional venture capital and private equity. In tandem with their unmatched clinical expertise and support, hospitals and health systems that recognize the opportunity to realize potentially significant results from private investments will prove to be a differentiating capital provider.

² 2Cain Brothers served as the exclusive financial advisor to Lumere in its sale to Global Healthcare Exchange, LLC (“GHX”)

Healthcare M&A Activity

Recent Selected Healthcare M&A Transactions (\$MM)

| Date | Target Name | Acquirer | EV | Enterprise Value / | | Description |
|------------|---|--|---------|--------------------|------------|--|
| | | | | LTM Rev. | LTM EBITDA | |
| 11/19/2021 | InnovaCare Health (Bain Capital Private Equity) | Bain Capital Private Equity | NA | NA | NA | Provider of integrated and value-based healthcare services |
| 11/18/2021 | Alliance Pharma | Ampersand Capital Partners | NA | NA | NA | Large and small molecule bioanalytical services |
| 11/18/2021 | Life Science Logistics | Blackstone Tactical Opportunities | NA | NA | NA | Provider of healthcare supply chain solutions |
| 11/17/2021 | BioAgilytix | Cinven (majority stake) | NA | NA | NA | Global contract research organization |
| 11/16/2021 | Genesis Research | GHO Capital | NA | NA | NA | Provider of tech-enabled Real-World Evidence and Health Economics and Outcomes Research services |
| 11/16/2021 | U.S. Endodontics Partners (Thurston Group) | Quad-C Management | NA | NA | NA | Endodontic platform with 80 offices in 28 states |
| 11/15/2021 | Behavioral Learning Center | The Stepping Stones Group (Five Arrows) | NA | NA | NA | Therapeutic and behavioral company |
| 11/15/2021 | Colorado Springs Urological Associates | Solaris Health (Lee Equity Partners) | NA | NA | NA | Provider of independent urological services |
| 11/9/2021 | Health Fidelity* | Edifecs (TA Associates and Francisco Partners) | NA | NA | NA | Provider of cloud-based risk adjustment solutions that project, detect, and capture all commensurate member risk |
| 11/10/2021 | Integra Managed Care | Anthem (NYSE: ANTM) | NA | NA | NA | Managed Long-Term Care Plan in New York that helps adults with long term care needs and disabilities live safely and independently in their own home |
| 11/10/2021 | Generate Life Sciences (GI Partners)* | CooperCompanies (NYSE: CO) | \$1,600 | \$6 | NA | Reproductive, newborn stem cell, genetic screening, medical device, and healthcare technology services |
| 11/9/2021 | Leiters (Kaiser Permanente Ventures, Mayo Clinic, Frazier Healthcare Partners, SV Health Investors H.I.G. BioHealth Partners) | Welsh, Carson, Anderson & Stowe | NA | NA | NA | FDA-registered 503B outsourcing provider of high-quality hospital and ophthalmology compounded sterile preparations. |
| 11/8/2021 | BioCare | The Vistria Group | NA | NA | NA | Specialty pharmaceutical distribution partner that provides distribution, specialty pharmacy and logistics services |
| 11/8/2021 | SurgCenter Development | Tenet Healthcare / United Surgical Partners International | \$1,200 | NA | NA | 92 ASCs and related ambulatory support services |
| 11/8/2021 | U.S. Oral Surgery Management (RiverGlade Capital) | Oak Hill Capital | NA | NA | NA | Provider of oral surgery management, partnering with over 140 oral surgeons across 18 states |
| 11/3/2021 | U.S. Medical Management (Centene's majority stake) | Rubicon Founders, Valtruis, Oak HC/FT and HLM Venture Partners | NA | NA | NA | A family of companies that provide home health services as well as an accountable care organization |
| 11/2/2021 | Guidemark Health | Arsenal Capital Partners | NA | NA | NA | Healthcare marketing communications, training, and medical education agency |
| 11/1/2021 | iCare Health Solutions (Pine Tree Equity Partners) | VSP Vision Care* | NA | NA | NA | Integrated specialty network and administrator of comprehensive ocular care services |
| 11/1/2021 | Lighthouse Lab Services (majority stake) | Martis Capital | NA | NA | NA | End-to-end provider of turnkey lab build-out and management services to clinical labs |

Healthcare Equity Private Placements Activity

Recent Selected Healthcare Equity Private Placements (\$MM)

| Date | Company | Investor(s) | Type | Amount | Description |
|------------|-----------------------------|--|----------------------------|--------------------------------|---|
| 11/17/2021 | aptihealth | Takeda Digital Ventures, Pivotal Life Sciences, Vista Credit Partners, Olive Tree Ventures, Claritas Capital, and What If Ventures | Series B | \$50 | Tech-driven behavioral health provider |
| 11/16/2021 | Trella Health | Cressey & Company (lead) and Panoramic Ventures | Undisclosed | Undisclosed | Provider of healthcare growth insights and performance analytics data |
| 11/8/2021 | Enhance Health | Bain Capital Insurance | Undisclosed | \$150 | Digital health insurance brokerage and care navigation platform focused on serving the Medicare Advantage market |
| 11/2/2021 | Infusion for Health | Oak HC/FT (lead), Cimarron Healthcare Capital | Undisclosed | \$50 | Network of ambulatory infusion centers |
| 11/1/2021 | Convergent Dental | Arboretum Ventures (lead), Long River Ventures and the Gund Foundation | Series C | \$40 | Dental equipment company |
| 10/26/2021 | Medable | Blackstone Growth and Tiger Global (co-leads), GSR Ventures, Sapphire Ventures and WTI | Series D | \$304.0 \$2.1 bln valuation | Patient-focused clinical research company offering a cloud offering for adoption of digital and decentralized clinical trials |
| 10/26/2021 | Stride | King River Capital (lead), Mastercard, Allstate, Venrock, NEA, and Fidelity's F-Prime Capital | Series C | \$47 | Portable benefits for independent workers for independent workers |
| 10/21/2021 | Workit Health | Insight Partners (lead), CVS Health Ventures, FirstMark Capital, BCBS Venture Fund, and 3L Capital | Series C | \$118 | Provider of virtual substance use disorder treatment |
| 10/20/2021 | Bardavon Health Innovations | Matrix Capital Management (lead), WestCap | Series C | \$90 | Workers' compensation and musculoskeletal health company |
| 10/20/2021 | Saama Technologies | Carlyle, Amgen Ventures, Intermountain Ventures, Merck Global Health Innovation Fund, McKesson Ventures, Northpond Ventures, Pfizer Ventures, and Population Health Partners | Strategic and Majority Sta | \$430 | AI-driven intelligent clinical cloud company serving the life science industry |
| 10/19/2021 | HistoWiz | Vivo Capital (lead), venBio, Asahi Kasei and Jon Oringer | Series A | \$32 | Digital histopathology service company |
| 10/14/2021 | VillageMD | Walgreens Boots Alliance | Undisclosed | \$5,200 | Provider of value-based primary care services |
| 10/13/2021 | Lark Health | Deerfield Management (lead), PFM Health Sciences, Franklin Templeton, King River Capital, Castlepeak, IPD and Olive Tree Capital | Series D | \$100 | AI solutions for virtual chronic and preventative healthcare |
| 10/13/2021 | Lively | B Capital Group (lead), Telstra Ventures and Costanoa Ventures | Series C | \$80 | Modern health savings account |
| 10/13/2021 | Sprinter Health | Andreessen Horowitz (lead), General Catalyst, Accel and Google Ventures | Series A | \$33 | On-demand mobile health company that sends full-time nurses and phlebotomists into the home |
| 10/12/2021 | Oshi Health | Flare Capital Partners, Bessemer Venture Partners and Frist Cressey Ventures (co-leads), CVS Health Ventures and Takeda Digital Ventures | Series A | \$23 | Virtual, patient-centered gastrointestinal care |
| 10/11/2021 | Bond Vet | Warburg Pincus | Undisclosed | \$170 | Tech-enabled brand of veterinary care clinics |
| 10/7/2021 | Brave Care | Mednax (lead) | Series B | \$25 | Pediatric healthcare and technology platform |


Public Equity Capital Markets Activity & Indices

Equity Indices Information as of November 19, 2021

| Index | Wk Open | Wk Close | Returns | |
|-----------------|---------|----------|---------|--------|
| | | | 52 Week | Weekly |
| DJIA | 36,100 | 35,602 | 20.8% | (1.4%) |
| S&P 500 | 4,683 | 4,698 | 31.2% | 0.3% |
| NASDAQ | 15,861 | 16,057 | 34.9% | 1.2% |
| Russell 2000 | 2,412 | 2,343 | 31.3% | (2.8%) |
| NYSE Healthcare | 22,151 | 23,190 | 20.2% | 4.7% |

| Cain Brothers Indicies | Returns | |
|-------------------------|---------|--------|
| | 52 Week | Weekly |
| Acute Care | 51.5% | (2.9%) |
| Alternate Site Services | (8.1%) | (5.0%) |
| Diagnostics | 26.4% | (2.9%) |
| Distribution | 17.5% | (3.5%) |
| Healthcare IT | 2.5% | (5.6%) |
| Healthcare REITs | 10.4% | (1.4%) |
| Managed Care | 24.5% | (4.0%) |
| Medical Technology | 18.7% | (0.8%) |
| Outsourced Services | 25.2% | (2.0%) |
| Pharma Services | 45.4% | 2.8% |
| Pharmacy | 36.3% | (2.0%) |
| Post-Acute Care | 12.7% | (2.7%) |

Cain Brothers Core Healthcare Indices (1YR Performance)



Recent Selected Healthcare IPOs and Follow-Ons (\$MM)

| Issuer (Ticker) | Pricing Date | Offering | Deal Value | Mkt Cap. ¹ | Offer Price | Current / Offer | Description |
|--------------------------------------|--------------|-----------|------------|-----------------------|-------------|-----------------|--|
| Paragon 28 (FNA) | 10/15/2021 | IPO | \$125 | \$1,391 | \$16.00 | 11.3% | Orthopedic medical device company |
| Cue Health (HLTH) | 9/24/2021 | IPO | \$200 | \$2,875 | \$16.00 | (37.9%) | Consumer focused healthcare IT company |
| Definitive Healthcare (DH) | 9/15/2021 | IPO | \$420 | \$4,288 | \$27.00 | 44.7% | Healthcare commercial intelligence solutions |
| Avantor (AVTR) | 9/15/2021 | Follow On | \$875 | \$25,884 | \$42.00 | (8.5%) | Critical products and services to customers in the biopharma and healthcare industries |
| Maravai LifeSciences (Nasdaq: MRVI)* | 9/10/2021 | Follow On | \$1,000 | \$15,400 | \$50.00 | (16.0%) | Data and analytics technology and services to healthcare organizations |

Tax-Exempt Debt Markets

Tax-Exempt Debt Information as of November 19, 2021

| Security | Current (%) | One Week Ago (%) | One Year Ago (%) |
|--|-------------|------------------|------------------|
| A-rated Tax-Exempt Hospital Bonds (30-Yr) | 1.84% | 1.83% | 2.12% |
| AA Tax-Exempt Hospital Bonds (30-Yr) | 1.64% | 1.63% | 1.82% |
| SIFMA (Variable Rate Demand Notes) | 0.04% | 0.04% | 0.11% |
| Revenue Bond Index | 2.49% | 2.46% | 2.61% |
| SIFMA/1 Month LIBOR | 44.44% | 44.44% | 73.33% |
| RBI/30 Yr Treasury (%) | 130.37% | 126.15% | 170.59% |
| 30-Year Floating to Fixed Swap (81% LIBOR) | 1.42% | 1.44% | 0.93% |

Tax-Exempt Healthcare Issuance Information¹ (\$MM)

| Borrower | Par | State | Rating | Maturity | Call, Put or Reprice* | Coupon | Yield to Call | Yield to Mat. | AAA |
|---|--------------------|-----------|----------------------|-------------|-----------------------|--------------|---------------|---------------|--------------|
| Sanford Health^(a) (Taxable) | \$249.845 | SD | NR / A+ / AA- | 2052 | MWC | 3.17% | 3.17% | N/A | 1.97% |
| Cedars-Sinai Health System ^(b) | \$1,034.365 | CA | Aa3 / AA- / AA- | 2051 | 2031 (C) | 5.00% | 1.91% | 3.51% | 1.54% |
| Cedars-Sinai Health System ^(b) (Taxable) | \$300.000 | CA | Aa3 / AA- / AA- | 2031 | MWC ^(b) | 2.29% | 2.29% | N/A | 1.60% |
| Bayhealth Medical Center Project | \$92.820 | DE | NR / AA- / AA | 2050 | 2032 (C) | 3.00% | 2.63% | 2.83% | 1.54% |
| Bayhealth Medical Center Project (Taxable) | \$26.340 | DE | NR / AA- / AA | 2051 | 2032 (C) | 3.41% | 3.41% | N/A | 2.02% |
| Good Shepherd Village at Endwell, Inc. Project | \$51.320 | NY | NR / NR / BBB- | 2047 | 2030 (C) | 4.00% | 2.50% | 3.32% | 1.54% |
| Otterbein Homes Obligated Group | \$24.485 | OH | NR / A / NR | 2046 | 2031 (C) | 4.00% | 2.31% | 3.15% | 1.54% |
| Otterbein Homes Obligated Group (Forward Delivery) | \$20.500 | OH | NR / A / NR | 2039 | 2033 (C) | 4.00% | 2.92% | 3.24% | 1.54% |
| Wesley Retirement Services | \$44.285 | IA | NR / NR / NR | 2051 | 2031 (C) | 4.00% | 3.05% | 3.56% | 1.54% |
| Plantation Village | \$32.740 | NC | NR / NR / BBB | 2052 | 2030 (C) | 4.00% | 2.55% | 3.44% | 1.54% |
| Maine Health and Higher Educational Facilities Authority ^(c) | \$20.435 | ME | A1 / AA / NR | 2051 | 2031 (C) | 2.75% | 2.93% | N/A | 1.54% |
| Total | \$1,897.135 | | | | | | | | |

*Key: NC = No Call, MWC = Make Whole Call, (C) = Par Call, (P) = 1st Put, (R) = Bloomberg, Capital IQ

a) Cain Brothers Sole-Managed Transaction

b) \$1.034 Bn Tranche: Overlapping final maturity with Coupon / YTC / YTM of 3.00% / 2.52% / 2.80%; \$300.000MM Tranche subject to Make Whole Call at 15 bps

c) Insured By: Assured Guaranty Municipal Corp. which provides 'A1' Moody's rating and 'AA' S&P rating

1. Bloomberg, Capital IQ

What's On Deck: Tax-Exempt Healthcare Issuances¹ (\$MM)

| Issuer | Date | Amount | Rating |
|--------|------|--------|--------|
| None | | | |

1. Bloomberg, Capital IQ

Corporate High Grade, High Yield & Leveraged Loan Market

Market Overview

High Yield

- Last week saw a \$99 million inflow, which follows the prior week's inflow of \$2.6 billion. YTD net outflows total \$14.1 billion, which compares to 2020 net inflows of \$44.9 billion


Leveraged Loans

- Leveraged loan funds saw a \$959 million inflow last week. There have been 44 inflows in 2021 totaling \$28.6 billion YTD following net outflows in 2020 totaling \$27.0 billion; Inflows totaled a more modest \$8.0 billion in 3Q21 following \$13.6 billion of inflows in 2Q21

HY Index Yield & Spread (YTD)



Weekly New Issue Volume (\$B)



New-Issue Clearing Yields¹ (\$MM)

| | 2Q21 | 3Q21 | 30-Day Rolling Average | | |
|---------------|-------|-------|------------------------|--------------|----------|
| | | | September 2021 | October 2021 | 11/18/21 |
| Overall | 4.64% | 4.78% | 4.66% | 4.87% | 4.63% |
| 4B | 2.98% | 3.45% | 3.44% | 2.82% | 3.65% |
| 2B | 4.99% | 5.02% | 4.87% | 4.82% | 4.70% |
| Middle Market | 5.15% | 5.75% | 6.21% | 5.82% | 5.34% |

Most Recent Healthcare High-Grade Issuances (\$MM)

| Date | Issuer | Security | Size | Ratings | Coupon | Maturity | Spread | IPT-Pricing |
|------------|----------------------------|----------|---------|------------------|--------|------------|---------|-------------|
| 11/16/2021 | Baxter International Inc | Sr Notes | \$800 | Baa2 / BBB / NR | 0.868% | 12/1/2023 | +35 | 15 bps |
| 11/16/2021 | Baxter International Inc | Sr Notes | \$300 | Baa2 / BBB / NR | 0.310% | 12/1/2023 | SOFR+26 | 15 bps |
| 11/16/2021 | Baxter International Inc | Sr Notes | \$1,400 | Baa2 / BBB / NR | 1.322% | 11/29/2024 | +45 | 15 bps |
| 11/16/2021 | Baxter International Inc | Sr Notes | \$300 | Baa2 / BBB / NR | 0.490% | 11/29/2024 | SOFR+44 | 15 bps |
| 11/16/2021 | Baxter International Inc | Sr Notes | \$1,450 | Baa2 / BBB / NR | 1.915% | 2/1/2027 | +65 | 15 bps |
| 11/16/2021 | Baxter International Inc | Sr Notes | \$1,250 | Baa2 / BBB / NR | 2.272% | 12/1/2028 | +75 | 20 bps |
| 11/16/2021 | Baxter International Inc | Sr Notes | \$1,550 | Baa2 / BBB / NR | 2.539% | 2/1/2032 | +90 | 20 bps |
| 11/16/2021 | Baxter International Inc | Sr Notes | \$750 | Baa2 / BBB / NR | 3.132% | 12/1/2051 | +110 | 20 bps |
| 11/15/2021 | Zimmer Bionet Holdings Inc | Sr Notes | \$850 | Baa3 / BBB / BBB | 1.450% | 11/22/2024 | +58 | 20 bps |
| 11/15/2021 | Zimmer Bionet Holdings Inc | Sr Notes | \$750 | Baa3 / BBB / BBB | 2.600% | 11/24/2031 | +98 | 22 bps |

Most Recent Healthcare High-Yield Issuances (\$MM)

| Date | Issuer | Security | Size | Ratings | Coupon | Maturity | Spread | Price Talk |
|------------|------------------------------------|----------------|---------|---------|--------|-----------|---------|-------------|
| 11/16/2021 | Tenet Healthcare | 1st Lien Notes | \$1,450 | B1/B+ | 4.375% | 1/15/2030 | 284 bps | 4.375% area |
| 11/2/2021 | Teva Pharmaceutical Industries (€) | Sr. Notes | \$1,269 | Ba2/BB- | 3.750% | 5/9/2027 | 421 bps | 4.00% area |

Most Recent Healthcare Leveraged Loan Issuances (\$MM)

| Date | Issuer | Ownership | Ratings | Use of Proceeds | Size | Pricing | Yield |
|------------|--------------------|-----------------|---------|-----------------|-------|---------------------|--------|
| 11/18/2021 | Duly Health & Care | Ares Management | B2 / B | Acquisition | \$80 | L+325, 0.75% @ 99.5 | 4.125% |
| 11/17/2021 | Carestream Dental | CD&R | B3 / B | Recap/Dividend | \$335 | L+450, 0.50% @ 99 | 5.250% |

Healthcare News

CVS Unveils New Health-Focused Retail Strategy, Explicit Move Into Primary Care¹

Healthcare Dive | November 19, 2021

CVS plans to close 900 stores (~10% of footprint) over the next three years as it works to keep pace with the evolving consumer patterns of ecommerce retail. The new strategy includes new store formats with a stronger focus on healthcare delivery. Healthcare being a highly local industry allows CVS to tailor its offerings to the communities they are located in. As of Sept 30, CVS had over 9,900 retail stores and 1,200 walk-in medical clinics, but the new strategy is focused on driving higher consumer engagement.

More Than 1.6 million Signed up for ACA Coverage Through 2 Weeks of Open Enrollment²

Fierce Healthcare | November 19, 2021

The Centers for Medicare & Medicaid Services (CMS) released an enrollment update on Healthcare.gov sign-ups since enrollment started November 1, and the number of sign-ups resembles the count that occurred over the same period in 2020. The Biden administration has made massive investments in outreach and marketing for 2022 open enrollment in an effort to increase participation. This includes quadrupling the number of ACA navigators to help assist consumers with choosing coverage, which represents a stark departure from the Trump administration's policy to cut enrollment funding.

BMA: Plans offering extra Medicare Advantage supplemental benefits grow by 43%³

Fierce Healthcare | November 22, 2021

The number of Medicare Advantage plans offering at least one of five recently expanded supplemental benefits increased by 43% from 2021 to the 2022 coverage year, a new analysis finds. The findings, released Thursday by the Better Medicare Alliance (BMA), come as supplemental benefits not offered by traditional Medicare have become a popular tool by insurers to market MA plans, an increasingly lucrative space for the industry. Overall, MA plans that offered at least one of the five expanded benefits increased from 575 in 2021 to 824 for 2022, according to the analysis conducted by consulting firm Milliman. The five supplemental benefits offered are adult day health services, home-based palliative care, in-home support services, caregiver support and therapeutic massages.

1. <https://www.healthcaredive.com/news/cvs-health-focused-retail-strategy-primary-care-stores-closing/610306/>

2. <https://www.fiercehealthcare.com/payer/cms-more-than-1-6m-signed-up-for-aca-coverage-through-two-weeks-open-enrollment>

3. <https://www.fiercehealthcare.com/payer/bma-plans-offering-extra-medicare-advantage-supplemental-benefits-grows-by-43>

Healthcare News Continued...

Policies and Reforms that could Reshape Healthcare in the \$2T bill just Passed by the House¹ **Fierce Healthcare | November 17, 2021**

The House passed a massive, roughly \$2 trillion infrastructure package called the Build Back Better Act that will give Medicare the power to narrowly negotiate prices on certain prescription drugs and close the Medicaid coverage gap. Passage of the legislation earned plaudits from some provider groups, but others were worried about the inclusion of cuts to disproportionate share hospital (DSH) payments that help facilities cover uncompensated care. Some of the big healthcare items in the package are:

- Closing the Medicaid coverage gap
- Offering several reforms to drug prices
- Expanding Medicare benefits to cover hearing aids
- Expanding Medicare-supported physician graduate medical education (GME) slots

Survey: US Hospital Patient Volumes Move Back Towards 2019 Levels² **McKinsey & Company | November 15, 2021**

In mid-2021, McKinsey surveyed leaders at 100 private-sector hospitals across the United States to understand how COVID-19 continued to impact hospital volume. We repeated the survey in October 2021, and found that, overall, hospital volumes are near 2019 levels, but continue to be impacted by waves of COVID-19. Of note: emergency department visits are above 2019 levels across all regions, and procedural volumes across all regions are close to their 2019 baseline. The flat operating-room volumes appear to be partially driven by relatively lower outpatient clinic volumes. Eight of the 10 specialties with the lowest relative clinic volumes are surgical specialties, with plastic surgery and ENT clinic volumes still between 8 percent and 12 percent below 2019 levels. Lower specialty clinic volumes appear to be due to capacity constraints, as a majority of respondents report access to care being worse now than pre-COVID-19. While most practices are trying to address access issues, the primary barrier is clinical staffing challenges. Ninety percent of respondents said staffing challenges are impacting elective procedure capacity, with plastic surgery, orthopedic surgery, and dermatology having some of the longest wait times for care.

Telemental Health Laws: Overview³

The National Law Review | November 23, 2021

It is well known that there is a shortage of behavioral health providers in the United States. Expanding telehealth technologies to increase patient access to psychiatrists, psychologists, counselors, therapists, and other behavioral health professionals has continued to gain attention and validation as the novel coronavirus disease (COVID-19) pandemic stretched into a second year. For most of 2021, health care providers dealt with the implications of COVID-19 on their professional practices. While providers struggled to care for patients amid COVID-19 contagion concerns, federal and state regulatory efforts that began in 2020, and have continued throughout 2021, have significantly helped ease the path to greater provision of services via telehealth. Now that we are more than a year and a half into the pandemic, federal and state governments have continued to support flexibilities put into place during the height of the pandemic that have promoted increased use of telehealth, both as lessons learned and to help lawmakers and regulators decide which temporary changes should, perhaps, be made more permanent.

1. <https://www.fiercehealthcare.com/payer/here-are-policies-and-reforms-could-reshape-healthcare-2t-bill-just-passed-house>


2. <https://www.mckinsey.com/industries/healthcare-systems-and-services/our-insights/survey-us-hospital-patient-volumes-move-back-towards-2019-levels>

3. <https://www.natlawreview.com/article/telemental-health-laws-overview>

November 30, 2021

Cain Brothers Industry Insights

Healthcare Weekly Market Report



This week's banker commentary:
First It Was Telehealth. Now It's...Teleplans?

Industry Insights

Contents

- Industry Insights
- Healthcare M&A Activity
- Healthcare Equity Private Placement Activity
- Public Equity Capital Markets Activity & Indices
- Tax-Exempt Debt Markets
- Corporate High Grade, High Yield & Leveraged Loan Market
- Healthcare News
- Cain Brothers Recent Transactions Spotlight
- Cain Brothers Recent Transactions



First It Was Telehealth. Now It's...Teleplans?

Banker Commentary by Mike Elizondo

Value-based care has taken the healthcare economy by storm, and many of my colleagues have written about value-based care. It's a daily consideration for us as healthcare investment bankers. Yet, value-based care often means different things to different groups. Some may consider value-based care as disease state specific program with capitated payments. Some may consider value-based care as full upside and downside risk for primary care providers to manage populations, while others may consider upside only arrangements.

One element that is clear is that value-based care is typically considered a provider function, a key element of which is the ability to provide and steer patients to virtual care across broad patient populations via technology, from asynchronous chats to video visits and remote patient monitoring. These functions have typically excluded payers, relegating payers to financing mechanisms vs. active participants in value-based care. Yet, payers are not sitting idly by.

Some payers have gone the direct route of investing in provider assets, vertically integrating to create close ties between insurance (i.e., healthcare financing) and the provision of care. Of the large insurers, United-Optum and Humana are most notable with significant acquisitions and investments in physician groups, primary care, and capitated clinic model businesses. These vertical integration strategies can be very effective due to the direct alignment of care and healthcare financing. Yet, these models require significant investments in infrastructure and in M&A/investments. Also, the ability to scale these solutions over large or multiple geographies is to be determined.

If vertical integration is not possible, how else can a payer be a meaningful player in value-based care and not relegated to a payment source? A relatively new phenomena is the advent of the virtual-first health plan. Via this plan design, payers seek to fundamentally change care patterns through benefit design, promoting virtual primary care as the triage point for members. The goal of these products is significant:

- Increased access: The availability of in-person visits can be a barrier to care as two points of failure (a provider's schedule and the member's schedule) are required to match up, often with a member needing to alter his/her schedule to accommodate a provider's schedule. Virtual care allows members to access care, anytime and anywhere, which in turn helps to improve overall member experience and satisfaction.

Industry Insights

- Quicker and more robust member data: By using a virtual care touchpoint, payers can begin to more quickly and accurately aggregate member data for use, as an example, to identify and intervene for members that may have an imminent healthcare event. Population health requires timely and accurate data, and using a virtual front door helps to bridge the health record gap.
- Lower overall costs: The fundamental premise of the cost of insurance is to pay for the underlying covered services. Therefore, designing benefits that emphasize lower cost of care venues should bring down the cost of a fully-insured product. Furthermore, self-insured employers are expected to more directly reap the benefits of a virtual-first benefit design through lower overall direct healthcare costs for their employee populations. Insurers estimate that virtual-first plan designs may reduce overall costs by 10-15%.

Virtual-first health plans do not aim to replace in person care. Rather, these benefit designs help “codify” a key premise of value-based care: the right care, at the right time, at the right cost. Importantly, virtual-first health plan designs help to bring value-based care to the commercial segment at a time when value-based care investments have largely been focused on the Medicare population. Importantly, investments in the health status of commercial membership, done effectively, should have meaningful downstream effects to the cost of care for future Medicare populations.

It's early days for virtual-first health plans, but I expect these plans to increase in popularity and in number. These plans will continue to change but the fundamental premise of this benefit design is promising.

Healthcare M&A Activity

Recent Selected Healthcare M&A Transactions (\$MM)

| Date | Target Name | Acquirer | EV | Enterprise Value / | | Description |
|------------|---|---|----------|--------------------|------------|--|
| | | | | LTM Rev. | LTM EBITDA | |
| 11/22/2021 | American Health Staffing Group (BelHealth Investment Partners) | Littlejohn & Co | NA | NA | NA | Provider of healthcare talent and technology solution |
| 11/22/2021 | athenahealth (Veritas Capital and Evergreen Coast Capital) | Hellman & Friedman and Bain Capital | \$17,000 | NA | NA | Provider of cloud-based enterprise software solutions for medical groups and health systems |
| 11/22/2021 | Silver Linings Hospice Care | Charter Healthcare Group (Pharos Capital Group) | NA | NA | NA | Provider of hospice care in New Mexico |
| 11/22/2021 | StateServ Medical | WindRose Health Investors | NA | NA | NA | Provider of durable medical equipment benefit management solutions to the post-acute care market |
| 11/19/2021 | InnovaCare Health (Bain Capital Private Equity) | Bain Capital Private Equity | NA | NA | NA | Provider of integrated and value-based healthcare services |
| 11/18/2021 | Alliance Pharma | Ampersand Capital Partners | NA | NA | NA | Large and small molecule bioanalytical services |
| 11/18/2021 | Life Science Logistics | Blackstone Tactical Opportunities | NA | NA | NA | Provider of healthcare supply chain solutions |
| 11/17/2021 | BioAgilytix | Cinven (majority stake) | NA | NA | NA | Global contract research organization |
| 11/16/2021 | Genesis Research | GHO Capital | NA | NA | NA | Provider of tech-enabled Real-World Evidence and Health Economics and Outcomes Research services |
| 11/16/2021 | U.S. Endodontics Partners (Thurston Group) | Quad-C Management | NA | NA | NA | Endodontic platform with 80 offices in 28 states |
| 11/15/2021 | Behavioral Learning Center | The Stepping Stones Group (Five Arrows) | NA | NA | NA | Therapeutic and behavioral company |
| 11/15/2021 | Colorado Springs Urological Associates | Solaris Health (Lee Equity Partners) | NA | NA | NA | Provider of independent urological services |
| 11/9/2021 | Health Fidelity* | Edifecs (TA Associates and Francisco Partners) | NA | NA | NA | Provider of cloud-based risk adjustment solutions that project, detect, and capture all commensurate member risk |
| 11/10/2021 | Integra Managed Care | Anthem (NYSE: ANTM) | NA | NA | NA | Managed Long-Term Care Plan in New York that helps adults with long term care needs and disabilities live safely and independently in their own home |
| 11/10/2021 | Generate Life Sciences (GI Partners)* | CooperCompanies (NYSE: CO) | \$1,600 | \$6 | NA | Reproductive, newborn stem cell, genetic screening, medical device, and healthcare technology services |
| 11/9/2021 | Leiters (Kaiser Permanente Ventures, Mayo Clinic, Frazier Healthcare Partners, SV Health Investors H.I.G. BioHealth Partners) | Welsh, Carson, Anderson & Stowe | NA | NA | NA | FDA-registered 503B outsourcing provider of high-quality hospital and ophthalmology compounded sterile preparations. |
| 11/8/2021 | BioCare | The Vistria Group | NA | NA | NA | Specialty pharmaceutical distribution partner that provides distribution, specialty pharmacy and logistics services |
| 11/8/2021 | SurgCenter Development | Tenet Healthcare / United Surgical Partners International | \$1,200 | NA | NA | 92 ASCs and related ambulatory support services |

Healthcare Equity Private Placements Activity

Recent Selected Healthcare Equity Private Placements (\$MM)

| Date | Company | Investor(s) | Type | Amount | Description |
|------------|-----------------------------|--|------------------------------|--------------------------------|---|
| 11/23/2021 | Luma Health | FTV Capital | Series C | \$130 | Patient engagement platform |
| 11/17/2021 | aptihealth | Takeda Digital Ventures, Pivotal Life Sciences, Vista Credit Partners, Olive Tree Ventures, Claritas Capital, and What If Ventures | Series B | \$50 | Tech-driven behavioral health provider |
| 11/16/2021 | Trella Health | Cressey & Company (lead) and Panoramic Ventures | Undisclosed | Undisclosed | Provider of healthcare growth insights and performance analytics data |
| 11/8/2021 | Enhance Health | Bain Capital Insurance | Undisclosed | \$150 | Digital health insurance brokerage and care navigation platform focused on serving the Medicare Advantage market |
| 11/2/2021 | Infusion for Health | Oak HC/FT (lead), Cimarron Healthcare Capital | Undisclosed | \$50 | Network of ambulatory infusion centers |
| 11/1/2021 | Convergent Dental | Arboretum Ventures (lead), Long River Ventures and the Gund Foundation | Series C | \$40 | Dental equipment company |
| 10/26/2021 | Medable | Blackstone Growth and Tiger Global (co-leads), GSR Ventures, Sapphire Ventures and WTI | Series D | \$304.0 \$2.1 bln valuation | Patient-focused clinical research company offering a cloud offering for adoption of digital and decentralized clinical trials |
| 10/26/2021 | Stride | King River Capital (lead), Mastercard, Allstate, Venrock, NEA, and Fidelity's F-Prime Capital | Series C | \$47 | Portable benefits for independent workers for independent workers |
| 10/21/2021 | Workit Health | Insight Partners (lead), CVS Health Ventures, FirstMark Capital, BCBS Venture Fund, and 3L Capital | Series C | \$118 | Provider of virtual substance use disorder treatment |
| 10/20/2021 | Bardavon Health Innovations | Matrix Capital Management (lead), WestCap | Series C | \$90 | Workers' compensation and musculoskeletal health company |
| 10/20/2021 | Saama Technologies | Carlyle, Amgen Ventures, Intermountain Ventures, Merck Global Health Innovation Fund, McKesson Ventures, Northpond Ventures, Pfizer Ventures, and Population Health Partners | Strategic and Majority Stake | \$430 | AI-driven intelligent clinical cloud company serving the life science industry |
| 10/19/2021 | HistoWiz | Vivo Capital (lead), venBio, Asahi Kasei and Jon Oringer | Series A | \$32 | Digital histopathology service company |
| 10/14/2021 | VillageMD | Walgreens Boots Alliance | Undisclosed | \$5,200 | Provider of value-based primary care services |
| 10/13/2021 | Lark Health | Deerfield Management (lead), PFM Health Sciences, Franklin Templeton, King River Capital, Castlepeak, IPD and Olive Tree Capital | Series D | \$100 | AI solutions for virtual chronic and preventative healthcare |
| 10/13/2021 | Lively | B Capital Group (lead), Telstra Ventures and Costanoa Ventures | Series C | \$80 | Modern health savings account |
| 10/13/2021 | Sprinter Health | Andreessen Horowitz (lead), General Catalyst, Accel and Google Ventures | Series A | \$33 | On-demand mobile health company that sends full-time nurses and phlebotomists into the home |
| 10/12/2021 | Oshi Health | Flare Capital Partners, Bessemer Venture Partners and Frist Cressey Ventures (co-leads), CVS Health Ventures and Takeda Digital Ventures | Series A | \$23 | Virtual, patient-centered gastrointestinal care |
| 10/11/2021 | Bond Vet | Warburg Pincus | Undisclosed | \$170 | Tech-enabled brand of veterinary care clinics |
| 10/7/2021 | Brave Care | Mednax (lead) | Series B | \$25 | Pediatric healthcare and technology platform |


Public Equity Capital Markets Activity & Indices

Equity Indices Information as of November 26, 2021

| Index | Wk Open | Wk Close | Returns | |
|-----------------|---------|----------|---------|--------|
| | | | 52 Week | Weekly |
| DJIA | 35,602 | 34,899 | 16.8% | (2.0%) |
| S&P 500 | 4,698 | 4,595 | 26.6% | (2.2%) |
| NASDAQ | 16,057 | 15,492 | 28.1% | (3.5%) |
| Russell 2000 | 2,343 | 2,246 | 21.7% | (4.1%) |
| NYSE Healthcare | 23,190 | 22,664 | 18.3% | (2.3%) |

| Cain Brothers Indicies | Returns | |
|-------------------------|---------|--------|
| | 52 Week | Weekly |
| Acute Care | 45.0% | (2.9%) |
| Alternate Site Services | (11.5%) | (3.7%) |
| Diagnostics | 26.3% | (0.0%) |
| Distribution | 13.5% | (0.9%) |
| Healthcare IT | 0.5% | (3.8%) |
| Healthcare REITs | 6.1% | (2.6%) |
| Managed Care | 25.0% | (0.7%) |
| Medical Technology | 16.0% | (3.3%) |
| Outsourced Services | 19.2% | (2.0%) |
| Pharma Services | 48.7% | (1.5%) |
| Pharmacy | 30.2% | (1.9%) |
| Post-Acute Care | 5.7% | (4.7%) |

Cain Brothers Core Healthcare Indices (1YR Performance)



Recent Selected Healthcare IPOs and Follow-Ons (\$MM)

| Issuer (Ticker) | Pricing Date | Offering | Deal Value | Mkt Cap. ¹ | Offer Price | Current / Offer | Description |
|--------------------------------------|--------------|-----------|------------|-----------------------|-------------|-----------------|--|
| Paragon 28 (FNA) | 10/15/2021 | IPO | \$125 | \$1,391 | \$16.00 | 11.3% | Orthopedic medical device company |
| Cue Health (HLTH) | 9/24/2021 | IPO | \$200 | \$2,875 | \$16.00 | (37.9%) | Consumer focused healthcare IT company |
| Definitive Healthcare (DH) | 9/15/2021 | IPO | \$420 | \$4,288 | \$27.00 | 44.7% | Healthcare commercial intelligence solutions |
| Avantor (AVTR) | 9/15/2021 | Follow On | \$875 | \$25,884 | \$42.00 | (8.5%) | Critical products and services to customers in the biopharma and healthcare industries |
| Maravai LifeSciences (Nasdaq: MRVI)* | 9/10/2021 | Follow On | \$1,000 | \$15,400 | \$50.00 | (16.0%) | Data and analytics technology and services to healthcare organizations |

Tax-Exempt Debt Markets

Tax-Exempt Debt Information as of November 26, 2021

| Security | Current (%) | One Week Ago (%) | One Year Ago (%) |
|--|-------------|------------------|------------------|
| A-rated Tax-Exempt Hospital Bonds (30-Yr) | 1.81% | 1.84% | 2.12% |
| AA Tax-Exempt Hospital Bonds (30-Yr) | 1.61% | 1.64% | 1.82% |
| SIFMA (Variable Rate Demand Notes) | 0.05% | 0.04% | 0.11% |
| Revenue Bond Index | 2.47% | 2.49% | 2.58% |
| SIFMA/1 Month LIBOR | 55.56% | 44.44% | 73.33% |
| RBI/30 Yr Treasury (%) | 127.98% | 130.37% | 164.33% |
| 30-Year Floating to Fixed Swap (81% LIBOR) | 1.39% | 1.42% | 0.98% |

Tax-Exempt Healthcare Issuance Information¹ (\$MM)

| Borrower | Par | State | Rating | Maturity | Call, Put or Reprice* | Coupon | Yield to Call | Yield to Mat. | AAA |
|--|-----------------|-------|--------------|----------|-----------------------|--------|---------------|---------------|-------|
| Buckingham Senior Living Community, Inc. Project ^(a) (Private Placement; Taxable) | \$24.580 | TX | NR / NR / NR | 2036 | NC | 7.50% | 7.50% | N/A | 1.83% |
| Buckingham Senior Living Community, Inc. Project ^(a) (Private Placement) | \$3.920 | TX | NR / NR / NR | 2037 | NC | 7.50% | 7.50% | N/A | 1.51% |
| Total | \$28.500 | | | | | | | | |

*Key: NC = No Call, MWC = Make Whole Call, (C) = Par Call, (P) = 1st Put, (R) = Reprice Date

a) Private Placement Agent: RBC Capital Markets

1. *Bloomberg, Capital IQ*

What's On Deck: Tax-Exempt Healthcare Issuances¹ (\$MM)

| Issuer | Date | Amount | Rating |
|---|-----------|-----------|------------------|
| Colorado Health Facilities Authority Revenue Bonds (Aberdeen Ridge), Series 2021 | Week of | \$138.995 | NR / NR / NR |
| Decatur Hospital Authority Hospital Revenue Bonds (Wise Health System) Taxable Series 2021A (For Purchase) Series 2021B (For Purchase) Series 2021C (For Purchase) | 12/2/2021 | \$56.805 | NR / BBB- / BBB- |
| The Charlotte-Mecklenburg Hospital Authority (North Carolina) Doing Business as Atrium Health Variable Rate Healthcare Revenue Bonds, Series 2018E Remarketing | 12/1/2021 | \$50.000 | Aa3 / AA- / NR |
| City of Valparaiso, Indiana Multifamily Housing Revenue Bonds (Green Oaks of Valparaiso Project), Series 2021 | 12/1/2021 | \$19.650 | NR / NR / NR |

1. *Bloomberg, Capital IQ*

Corporate High Grade, High Yield & Leveraged Loan Market

Market Overview


High Yield

- Last week saw a \$3.3 billion outflow, which follows the prior week's inflow of \$99 million. YTD net outflows total \$14.8 billion, which compares to 2020 net inflows of \$44.9 billion


Leveraged Loans

- Leveraged loan funds saw a \$850 million inflow last week. There have been 45 inflows in 2021 totaling \$29.5 billion YTD following net outflows in 2020 totaling \$27.0 billion; Inflows totaled a more modest \$8.0 billion in 3Q21 following \$13.6 billion of inflows in 2Q21

HY Index Yield & Spread (YTD)



Weekly New Issue Volume (\$B)



New-Issue Clearing Yields¹ (\$MM)

| | 2Q21 | 3Q21 | 30-Day Rolling Average | | |
|---------------|-------|-------|------------------------|--------------|----------|
| | | | September 2021 | October 2021 | 11/24/21 |
| Overall | 4.64% | 4.78% | 4.66% | 4.87% | 4.60% |
| 4B | 2.98% | 3.45% | 3.44% | 2.82% | 3.59% |
| 2B | 4.99% | 5.02% | 4.87% | 4.82% | 4.68% |
| Middle Market | 5.15% | 5.75% | 6.21% | 5.82% | 5.35% |

Most Recent Healthcare High-Grade Issuances (\$MM)

| Date | Issuer | Security | Size | Ratings | Coupon | Maturity | Spread | IPT-Pricing |
|------------|--------------------------|----------|---------|-----------------|--------|------------|---------|-------------|
| 11/16/2021 | Baxter International Inc | Sr Notes | \$800 | Baa2 / BBB / NR | 0.868% | 12/1/2023 | +35 | 15 bps |
| 11/16/2021 | Baxter International Inc | Sr Notes | \$300 | Baa2 / BBB / NR | 0.310% | 12/1/2023 | SOFR+26 | 15 bps |
| 11/16/2021 | Baxter International Inc | Sr Notes | \$1,400 | Baa2 / BBB / NR | 1.322% | 11/29/2024 | +45 | 15 bps |
| 11/16/2021 | Baxter International Inc | Sr Notes | \$300 | Baa2 / BBB / NR | 0.490% | 11/29/2024 | SOFR+44 | 15 bps |
| 11/16/2021 | Baxter International Inc | Sr Notes | \$1,450 | Baa2 / BBB / NR | 1.915% | 2/1/2027 | +65 | 15 bps |
| 11/16/2021 | Baxter International Inc | Sr Notes | \$1,250 | Baa2 / BBB / NR | 2.272% | 12/1/2028 | +75 | 20 bps |
| 11/16/2021 | Baxter International Inc | Sr Notes | \$1,550 | Baa2 / BBB / NR | 2.539% | 2/1/2032 | +90 | 20 bps |
| 11/16/2021 | Baxter International Inc | Sr Notes | \$750 | Baa2 / BBB / NR | 3.132% | 12/1/2051 | +110 | 20 bps |

Most Recent Healthcare High-Yield Issuances (\$MM)

| Date | Issuer | Security | Size | Ratings | Coupon | Maturity | Spread | Price Talk |
|------------|------------------------------------|----------------|---------|---------|--------|-----------|---------|-------------|
| 11/16/2021 | Tenet Healthcare | 1st Lien Notes | \$1,450 | B1/B+ | 4.375% | 1/15/2030 | 284 bps | 4.375% area |
| 11/2/2021 | Teva Pharmaceutical Industries (€) | Sr. Notes | \$1,269 | Ba2/BB- | 3.750% | 5/9/2027 | 421 bps | 4.00% area |
| 11/2/2021 | Teva Pharmaceutical Industries (€) | Sr. Notes | \$1,731 | Ba2/BB- | 4.375% | 5/9/2030 | 465 bps | 4.625% area |

Most Recent Healthcare Leveraged Loan Issuances (\$MM)

| Date | Issuer | Ownership | Ratings | Use of Proceeds | Size | Pricing | Yield |
|------------|--------------------|---|---------|-----------------|-------|----------------------|--------|
| 11/23/2021 | Eversana* | JLL Partners / Water Street Healthcare Partners | B3 / B- | Acquisition | \$725 | L+450, 0.50% @ 99.5 | 5.125% |
| 11/22/2021 | Soliant Health Inc | Olympus Partners | B2 / B+ | Recap/Dividend | \$180 | L+425, 0.75% @ 99.75 | 5.063% |
| 11/18/2021 | Duly Health & Care | Ares Management | B2 / B | Acquisition | \$80 | L+325, 0.75% @ 99.5 | 4.125% |

Sources: Lipper FMI, Morgan Markets

1. 4B rating (BB/Ba2), 2B rating (B/B2)

2. 90-day rolling average

* Denotes Cain Brothers/KeyBanc Capital Markets participation

Healthcare News

Humana: Value-Based Contracts Led To Better Care, Outcomes During Covid-19¹

Fierce Healthcare | November 24, 2021

Humana Medicare Advantage members receiving value-based care had more preventive care, lower costs and better outcomes in 2020 compared to those in traditional Medicare, according to Humana's latest annual value-based care report. Humana's report found that despite delays in care during the pandemic, value-based care physicians fared far better in terms of quality than those in non-value-based models across every care category. Value-based physicians were also more adaptable during the rapidly changing healthcare landscape that year, able to implement tech like telehealth quicker and sustain use for longer. The physicians benefited as well, the report found: Those in value-based contracts received more of the overall healthcare dollar, earning 17.5 cents of every dollar spent compared to 6.7 cents for non-value-based physicians.

Labor, Supply Chain Pressures Mount For US Hospitals, Fitch Says²

Healthcare Dive | November 22, 2021

Pressure on U.S. hospital margins is intensifying as a scarcity of workers drives up labor costs and supply chain problems ripple across the healthcare sector, according to a report out Friday from Fitch Ratings. Healthcare and pharmaceutical companies have survived the coronavirus pandemic thus far with their credit profiles largely intact. Now, wage inflation and supply chain disruptions signal the potential for lost revenue and greater margin pressure in the near term as costs rise, the ratings agency said. Staffing challenges are especially acute in skilled nursing, senior housing and in-patient behavioral health, posing a greater risk to recovery for the hardest hit operators as the pandemic stretches on, according to the report. The worker shortage is driving up wages and leading to greater use of more expensive temporary help. hospitals report staff burnout and high rates of employee turnover. Non-hospital providers face a more dire scenario where "staffing is insufficient to meet demand," resulting in lower patient admissions, the Fitch report said.

New Health Plans Offer Twists on Existing Options, With a Dose of 'Buyer Beware'³

US News | November 2, 2021

Fueled by consumer frustration with high premiums and deductibles, two new offerings promise a means for consumers to take control of their health care costs. But experts say they pose risks. While they're still niche products, these nontraditional options say they aim to soothe consumer frustration with high premiums and deductibles by harnessing the growing availability of price information or patients' newfound comfort with online health services. One such offering, from insurer Sidecar Health, pays consumers its estimated cash price for each medical visit and lets them shop for the best deal. Another, from Antidote Health, isn't insurance, but offers access to online-only primary care for a small monthly fee. While the image the plans present is one of consumers taking control of their health care costs, the "reality is likely the opposite," said Dania Palanker, assistant research professor at the Center on Health Insurance Reforms at Georgetown University. That's because they are not Affordable Care Act plans. They are not comprehensive medical insurance and could leave patients responsible for hundreds or even thousands of dollars, either because benefits cover only part of a medical bill or because of other plan limitations. Some of these companies like Antidote describe themselves as "digital healthcare companies," not insurance, providing technical and administrative support to physicians.

Healthcare News Continued...

Kamala Harris Announces \$1.5 Billion Healthcare Investment For Underserved Communities As Part Of Larger Equity Push¹

Forbes | November 22, 2021

Vice President Kamala Harris announced \$1.5 billion in funding by the Biden administration for several healthcare initiatives including service programs for medical students and professionals to work in hard-hit communities in exchange for scholarships and loan repayments, part of the White House's larger effort at "keeping equity centered" in its pandemic response. The investment from the coronavirus relief package will go to several federal programs dealing with workforce shortages and healthcare disparities, according to the White House press release: the National Health Service Corps, Nurse Corps and Substance Use Disorder Treatment and Recovery programs. The initiatives provide scholarships and loan repayment funding to students and healthcare professionals in return for service commitments in under-resourced communities. The new funding is expected to support more than 22,700 doctors, dentists, nurses and behavioral health professionals.

Growth Opportunities for 5G Wireless in the US Healthcare Market: Implementing Private 5G Healthcare Networks²

BusinessWire/ResearchandMarkets.com | November 30, 2021

5G refers to the 5th generation of wireless technology that promises to deliver game-changing benefits to users, including dramatically increased bandwidth, higher speed, reduced latency, and network slicing. The bottom line: 5G will accommodate dramatically more devices, media, and users. This will especially impact the Internet of Things, which will result in a huge increase in the number of remote monitors and sensors that will allow patients to be tracked while on the go. The new level of patient-generated healthcare data will permit enhanced analysis of various conditions and diseases, which will support personalized medicine and improved outcomes. 5G technology will also enable wireless carriers to offer providers and payers new ways to manage the spectrum. This will permit the development of wireless private networks that are able to support a healthcare enterprise's evolving IT needs. There will be numerous opportunities for healthcare enterprises to gather and transmit huge data files, such as teleradiology images, quickly and securely.

Physical Therapy Joining Care-at-Home Movement³

Healthcare Innovation | November 22, 2021

One of the key trends of 2021 is the shift of care to the home setting, ranging from acute hospital at home to skilled nursing at home. Now physical therapy has jumped on the bandwagon, too. Georgia-based Emory Healthcare has partnered with a California company called Luna to bring outpatient physical therapy treatment to patients' homes. Luna says its turnkey service helps health systems like Emory improve the profitability of their rehabilitation services by expanding access to care, improving adherence, enhancing patient experience, and reducing referral leakage. "The pandemic really accelerated the way we think about off-site care," said Scott Boden, M.D., director of the Emory Orthopaedics & Spine Center and vice president for business innovation for Emory Healthcare. "We very quickly had to reinvent not only how we diagnose patients, and figure out if they needed surgery, but also how we treat them nonoperatively, including with rehabilitation. That really accelerated the development of the toolbox for doing remote physical therapy." That toolbox includes on-site therapy, and telehealth PT, which is appropriate in some other situations. In-home PT makes sense, Boden added, if somebody doesn't live close enough to one of Emory's bricks-and-mortar PT sites. "It depends on geography, diagnosis and stage of rehabilitation, as to which of those options are the best." The partnership with Luna removes the barriers to care of time and transportation and makes it as easy as possible for patients to complete their treatment plan.

1. <https://www.forbes.com/sites/teakvetenadze/2021/11/22/kamala-harris-announces-15-billion-healthcare-investment-for-underserved-communities-as-part-of-larger-equity-push/?sh=45f757fe543c>

2. <https://www.businesswire.com/news/home/20211130005514/en/Growth-Opportunities-for-5G-Wireless-in-the-US-Healthcare-Market-Implementing-Private-5G-Healthcare-Networks---ResearchAndMarkets.com>

3. <https://www.hcinnovationgroup.com/population-health-management/home-based-care/article/21247561/physical-therapy-joining-careathome-movement>